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SUMMARY
The work of Kohler and Milstein (1975) on the production of immortal cell 
lines secreting antibody in conjunction with that of Miles and Hales (1968) on the 
concept of the immunometric assay and later Woodhead at al (1974) with the two-site 
immunometric assay has caused a revolution in the exploitation of antibodies as 
diagnostic reagents. The properties of monoclonal antibodies are particularly suited to 
application in immunometric assays and overcome all the major problems associated 
with the use of conventional antisera. The work in this thesis is concerned with the 
production of monoclonal antibodies with suitable characteristics and their application 
to immunoassays for protein and peptide hormones.
A structural and clinical perspective on growth hormone introduces 
chapter three, followed by a review of methods utilised in the measurement of its 
concentration. The major part of the chapter deals with the production of monoclonal 
antibodies to human growth hormone and the development of a two-site 
immunoradiometric assay. Over one thousand antibody secreting hybrids were 
identified. Relative affinity estimates were used to select the most suitable for use in 
assay development. The final assay is precise, sensitive, offers a wide working range 
and can be completed within the day. Assay specificity was defined by recovery 
estimates of exogenous growth hormone in the presence of elevated endogenous 
concentrations of prolactin and placental lactogen. The clinical utility of the assay is 
demonstrated with reference to dynamic function tests in comparison with a well 
established radioimmunoassay. The long term stability of the assay is proven with UK 
EQAS data during the first year of routine application.
Chapter four relates to parathyroid hormone. Structural and physiological 
considerations determine the strategy adopted in attempts to produce monoclonal 
antibodies. The five isolated monoclonal antibodies were evaluated on the basis of 
specificity and relative affinity for 1-84 human PTH. A sensitive and precise two-site
26
immunoradiometric assay for intact 1-84 PTH was developed and validated. Clinical 
studies with this assay show good discrimination between normal subjects and patients 
with primary hyperparathyroidism.
Chapter five describes attempts to produce monoclonal antibodies to the 
recently discovered atrial natriuretic peptide, ANF 99-126. Initial hybridisation 
experiments were disappointing despite the presence of antibodies in the serum of 
donor mice. The screening procedure was extensively investigated and the 
radioiodination procedure discovered to be of key importance. A post-iodination 
purification method utilising HPLC was developed which allows the isolation of 
mono-iodo ANF 99-126 from the di-iodinated and methionine sulphoxide 
derivatives. The efficiency of the sheep anti-mouse solid-phase separation used in the 
screening assay was also evaluated.
Chapter six describes attempts to find a combination of available anti-ANF 
antibodies suitable for use in a two-site assay. The four monoclonal antibodies and 
one polyclonal antiserum examined failed to provide a complementary pair. The best 
of these antibodies in terms of avidity, a monoclonal antibody, was utilised in the 
development of a solid-phase radioimmunoassay based initially on Sepharose 
particles and subsequently on magnetic particles. Direct measurement of ANF in 
plasma was not possible, therefore a plasma extraction method was developed. 
Comparison of results with published data suggested that the assay may have a 
positive bias. Studies on the oxidation state of standard materials and the relative 
antibody affinity for oxidised standard and radiolabel in contrast to affinity for non­
oxidised ANF are detailed. Examination of the elution of ANF from ODS cartridges 
revealed the presence of an unidentified cross reactant.
Chapter seven summarises the general findings from this project, highlights 
problem areas and offers some suggestions for the future. In broad terms the project 
was successful, its major aims having been achieved.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 INTRODUCTION
The development of clinically useful immunoassays requires a knowledge 
of the immune system, particularly the theory of antibody production, the structure 
and properties of antibodies, immunoassay design and the physiology and 
pathophysiology relating to the substances of interest.
1.1.2 The Immune System
The vertebrate immune system is capable of mediating immunity in both a 
non-specific and a specific manner. Non-specific immunity is effected by physical 
and chemical barriers as well as cellular components of the reticuloendothelial 
system. While this type of immunity is not enhanced by repeated exposure to 
antigen it does play a role in the development of acquired immunity (Unanue, 
1972). Specific acquired immunity is enhanced by repeated exposure to antigen and 
is mediated by lymphocytes. These lymphoid system cells can be divided into two 
groups dependant upon the lymphoid organ of origin (Mitchell & Miller,1968). B 
cells originate from the foetal liver and bone marrow while T cells originate from 
the thymus. It is in this environment that the lymphocytes learn to discriminate self 
from non-self and acquire their repertoire of specific antigen receptors and 
therefore become committed to a single antigenic specificity for their life span 
(Burnet, 1959). Mature T and B lymphocytes migrate to the secondary lymphoid 
organs, the spleen and lymph nodes, where they interact with macrophages and 
each other to mount an immune response.
1.1.3 The Humoral Immune Response
A humoral response is one that results in the production of antibodies by B
lymphocytes. The activity of the B lymphocytes is regulated directly or indirectly 
by two sub sets of T lymphocytes known as T-helper (Tjj) and T-suppressor (T§)
28
cells ( Jandinski et al, 1976; Cantor et al, 1976).
The initial stages of an antibody response involve the transport of antigen
from the periphery to lymph nodes and their non-specific engulfment by
macrophages. Once internalised the antigen is partially degraded and fragments of
it appear on the cell surface complexed with I region associated (la) antigens which
are coded for by the I region of the major histocompatibility complex (MHC). 
These antigen fragment-Ia antigen complexes interact with Tjj cell receptors,
which are specific for both components of the complex, resulting in proliferation by 
clonal expansion of the selected Tjj cells. These T jj cells are now primed and will
only interact with B lymphocytes which present antigen and la antigen in the
orientation as originally seen on the macrophage. This phenomenon is known as
MHC restriction and appears to be antigen-specific.
B lymphocytes also bind to antigen, but unlike the interaction with
macrophages this process is specific being mediated by cell surface
immunoglobulin. Internalisation, degradation and complexing with la antigens
follows resulting in cell surface presentation of antigen fragment-Ia antigen
complex identical to the analogous complexes on the macrophages involved in the 
priming of Tfj cells. Interaction between Tjj and B lymphocytes provides the
stimulus that leads to the differentiation of B cells into either plasma cells, which 
are short lived and devoted to the production of antibody, or memory cells, which 
are long lived and do not secrete antibody.
When an antigen is encountered by the immune system for the first time the 
response observed is weak relative to that seen on subsequent exposure. This is 
because only a small number of lymphocytes will be able to bind to the antigen. 
Exposure to antigen results in clonal proliferation as described above thus on 
subsequent exposure the response is more vigorous.
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1.1.4 Genetic Control of the Murine Immune Response
Autosomal dominant genes controlling the immune response to various 
antigens have been reported (Benacerraf & McDevitt, 1972). These immune 
response (Ir) genes have been mapped to the I region of the major 
histocompatibility complex (H-2 in the mouse) (Katz et al, 1975). The la antigens 
are the products of these genes and are expressed predominantly on B lymphocytes 
and macrophages where they effect the antigen-specific MHC restriction of T cells 
(Schwartz, 1986 ; Unane et al, 1974). A number of theories have been proposed to 
account for the antigen-specific effects of the la antigens on the immune response 
but it is still unclear which is correct ( Katz et al, 1975).
1.1.5 Immunogenicity
The immunogenicity of a molecule relates to its ability to induce an immune 
response ie. produce antibodies. Antigenicity in contrast relates only to the ability to 
combine with antibody.
Generally the greater the phylogenetic distance between the immunogen and 
the recipient the more vigorous the response. Highly conserved proteins tend to 
illicit weak responses because structural differences from the host's self-proteins 
are limited (Lanzavecchia, 1986).
To be immunogenic a molecule must posses two distinct epitopes 
(Lanzavecchia, 1986). These are required since the molecule must combine with 
surface antibody on B cells and also after degradation inside the B cell or 
macrophage, bind simultaneously to the la antigens on the B cell/macrophage 
surface and the T cell receptor (Goodman, 1983). The former epitope determines 
the specificity of the antibodies produced and is an absolute requirement in eliciting 
an antibody response.
The requirements for immunogenicity can be divided into two categories, 
those which are intrinsic to the molecule and those which are extrinsic (Berzofsky,
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1985). Intrinsic properties relate to the epitope which binds to the B cell and include 
accessibility (ie tertiary structure) and hydrophilicity. Extrinsic properties relate to 
the la antigen-T cell receptor binding site, recognition of which is restricted by a 
number of variables all of which are a function of the host and therefore change 
depending on the species or individual chosen for immunisation.
From the above it can be seen that molecules fail to be immunogenic for one 
of two reasons. Firstly they may be too small to posses an la antigen-T cell 
receptor binding site in addition to an epitope recognised by B lymphocytes and as 
such are classified as haptens. Alternatively they share a high degree of sequence 
homology with a recipient molecule and as such are not recognised as foreign due 
to MHC restriction of the immune response. Both of these problems can be 
overcome by conjugating the molecule to an immunogenic carrier molecule. This 
provides the la antigen-T cell receptor binding site in the case of haptens and an 
alternative binding site in the case of MHC restriction. In the latter case the 
immunisation of a number of inbred strains of animal may be an additional or 
alternative solution.
1.1.6 The Structure of Immunoglobulins
All antibodies are immunoglobulins. Immunoglobulins are made up of two 
identical heavy and two identical light chains held together by inter-chain 
disulphide bonds (Figure 1.1). Valentine and Green (1967) elegantly demonstrated 
the structure of immunoglobulins to be Y shaped hinged molecules with the antigen 
combining site at the end of each of the two arms. Sequencing studies on a number 
of myeloma proteins have revealed that the N-terminal portions of both heavy and 
light chains show considerable variability whereas the remaining parts of the chains 
are relatively constant. The site of antigen binding is believed to be the N-terminal 
variable regions.
Based upon the structure of their heavy chain constant regions,
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Figure 1.1 Model of an immunoglobuln molecule
immunoglobulins, are divided in classes and may be further divided into subclasses. 
The major classes/subclasses in the mouse, for example, are IgGl, IgG2a, IgG2b, 
IgA and IgM. Light chain constant regions also exist in two isotopic forms known 
as k and X . Both light chains in a given immunoglobulin molecule are identical.
1.1.7 Antibody Antigen Interaction
Antibodies and antigens interact by spatial complementarity not by covalent 
bonding. The forces binding antigen to antibody become large as intermolecular 
distances become small. These intermolecular forces may be classified under four 
headings.
1) Electrostatic
These are due to the attraction between oppositely charged ionic groups on 
the two protein side-chains. The force of attraction (F) is inversely proportional to 
the square of the distance (d) between the charges
F a  l/kpjd^
where k ^  is the dielectric constant. Since the dielectric constant of water is
extremely high, exclusion of water molecules through the contiguity of the 
interacting molecules would greatly increase the value of F.
2) Hydrogen Bonding
Hydrogen bonding is the formation of hydrogen bridges between hydrophilic 
groups such as -OH, -NH2 and -COOH and depends upon the close approach of 
the two molecules carrying these groups. Hydrogen bonds are essentially 
electrostatic in nature and exclusion of water enhances binding energy.
3) Hydrophobic
The side chains of amino acids such as valine, leucine and phenylalanine are 
hydrophobic and in aqueous solution the water molecules with which they come 
into contact are not hydrogen bonded and are therefore in a higher energy state than
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they would be if free to form more hydrogen bonds with themselves or some other 
hydrophilic molecule. If hydrophobic molecules on the surfaces of two proteins 
come into close contact so as to exclude water molecules between them, the net 
surface in contact with water is reduced. Thus more water molecules are in the 
hydrogen bonded state than were when the two proteins were apart. This means that 
the proteins take up a lower energy state and hence a preferred configuration when 
they are combined rather than separated. There is therefore a force of attraction 
between them.
4) Van der Waals
These are forces between molecules which depend upon interaction 
between external 'electron clouds'. The nature of this interaction can be likened to a 
temporary perturbation of electrons in one molecule effectively forming a dipole 
which induces a dipole in the other molecule, the two dipoles having a force of 
attraction between them. As the electrons swing back through the equilibrium 
position and beyond the dipoles oscillate. The force of attraction is inversely 
proportional to the seventh power of the distance ie.
F a  l/d7
and as a result this rises as the interacting molecules come closer together.
Common to all four types of force is their dependence upon the close 
approach of both molecules before the force becomes of significant magnitude and 
this force increases if water is excluded.
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1.2 PRODUCTION OF POLYCLONAL ANTISERA
1.2.1 Introduction
There are no generally accepted guidelines for the production of antisera. 
The literature contains reports of a multitude of strategies many of which are 
prejudice or anecdote. However, a number of key factors can be identified as 
having relevance to the outcome.
1.2.2 The Immunogen
Generally proteins having a molecular weight in excess of 5000 readily 
stimulate the production of avid antibodies. Some proteins (such as insulin) may 
form dimers or larger aggregates in solution and this probably increases their 
immunogenicity. Peptides of low molecular weight are generally less immunogenic 
although a number of workers have successfully raised antisera to unmodified octa, 
nona and deca peptides. Molecules which are not in themselves immunogenic will 
require conjugation to a larger immunogenic molecule such as albumin or keyhole 
limpet haemocyanin (KLH). The specificity of antisera produced from conjugates 
may be effected by the haptens orientation after coupling. Many methods of 
coupling are described in the literature offering some choice of attachment point.
1.2.3 Choice of Adjuvant
The most commonly used adjuvant is Freunds which comes in two forms, 
complete and incomplete. Freunds complete adjuvant (FCA) contains 
Mycobacterium tuberculosis of which the active component is muramyl dipeptide 
(Ellouz et al, 1974). There are two components to the mechanism of action of 
adjuvants. Firstly they form a depot which protects the antigen from catabolism and 
slowly releases it over an extended period of time and secondly they stimulate the 
immune response in a non-specific manner. In the case of complete adjuvant this
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involves local formation of granulomas which are rich in macrophages and 
immunocompetent cells (Warren et al, 1986). Normally FCA is used for primary 
immunisation while incomplete adjuvant (FIA) is used for subsequent booster 
injections.
1.2.4 Choice of Animal Species and Strain
This choice will be dependent upon the immunogen and differences in 
structure/sequence relative to those of the proposed host. The volume of antiserum 
required may be a factor as may be any particular animal handling/housing 
requirements.
Most polyclonal antisera for immunoassay purposes have been produced in 
rabbits, guinea-pigs, sheep or donkeys. Occasionally the choice of species is 
particularly restricted eg the use of guinea-pigs for the production of antisera to 
insulin.
1.2.5 Route of Immunisation
Commonly used routes are intramuscular, subcutaneous, intradermal and 
intraperitoneal. It is generally accepted practice to use several sites except in the 
case of the intraperitoneal route where only one site is preferred. Some workers 
have used intranodal injections with success but since this requires surgery and the 
success rates have not been shown to be significantly better than standard routes the 
technique has not been widely used.
1.2.6 Quantity of Immunogen
Doses have been recommended which range from as little as 1 - 50 pg for 
mice (Campbell, 1984) up to several mg for larger animals (Hum & Landon, 1971). 
The general rule for the achievement of maximum avidity is to reduce the amount 
of immunogen to the minimum effective level. In some cases availabilty/cost of
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immunogen w ill be an overriding factor.
1.3 MONOCLONAL ANTIBODY PRODUCTION
1.3.1. Introduction
Immunological methods suffer from several limitations which significantly restrict 
their applicability and usefulness. Firstly, there are often substantial practical 
difficulties in purification of antigens from human sources, for use in immunisation, 
standardisation and the isolation of specific antibodies. Secondly, the generation 
and continued production of antibody with appropriate specificity and other 
properties is not always easy. All conventional antisera contain complex mixtures 
of different antibodies of varying specificity and avidity, recognising various 
aspects of antigenic structure. Further, individual sera from different animals, or 
even at different times in a given animal, differ in the mixture of antibodies they 
contain and so do not necessarily have the same properties. The heterogeneity of 
the immune response in vivo results from the fact that antigen indirectly stimulates 
the clonal proliferation of many different antibody-producing cells (McConnell et 
al, 1981), each one secreting a single antibody species. The complex (polyclonal) 
mixture of antibodies which results is extremely difficult to resolve into its 
individual components, and only relatively crude fractionation on the basis of gross 
differences in specificity, or avidity is generally possible.
The development of techniques for the production of monoclonal antibodies 
(Kohler & Milstein, 1975) enormously expanded the potential for the application of 
antibodies as analytical and preparative reagents. Monoclonal antibodies are the 
products of individual cloned cell lines which may be grown in vitro, and as such 
they are homogeneous preparations with defined specificity and affinity.
Lymphocytes from immunised animals will not themselves grow in vitro but 
by fusion with myeloma cell lines they may be immortalised. The hybrid cells
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(hybridoma) which result retain the important properties of both parent cell types. 
They continue to produce antibody characteristic of the lymphocyte and also grow 
indefinitely in culture as myeloma cells.
1.3.2 Rationale of Cell Fusion
Almost any two cell types can be made to fuse by the addition of Sendai virus, 
lysolecithin or polyethylene glycol (PEG). PEG is now the agent of choice. The 
mechanism of fusion is poorly understood (Knutton & Pasternak, 1979; White & 
Helenius, 1980). The fusion of the plasma membranes results in the formation of 
heterokaryons which posses two or more nuclei. At the next division, the nuclei 
fuse, and a hybrid cell results.
Fusion is a relatively rare event, even when PEG is used. Thus, if tumour 
cells are fused with normal cells, the culture will be rapidly overgrown by unfused 
tumour cells. The most popular strategy for preventing this is that devised by 
Littlefield (1964).
The main biosynthetic pathway for purines and pyrimidines can be blocked 
by the folic acid antagonist aminopterin. However the cell can still synthesise DNA 
via the so called salvage pathways, in which preformed nucleotides are recycled. 
These pathways depend on the enzymes thymidine kinase (TK) and hypoxanthine 
guanine phosphoribosyl transferase (HGPRT). If one or other enzyme is absent 
DNA synthesis ceases. The cell can however be ’’rescued" by fusion with another 
cell which supplies the missing enzyme. Thus, if spleen cells (which possess TK 
and HGPRT but die in culture) are fused with cell lacking TK or HGPRT only 
hybrid cells will grow in a medium containing hypoxanthine, aminopterin and 
thymidine (HAT medium).
Mutant myeloma cells lacking HGPRT are produced by the use of 
thioguanine which is incorporated into DNA via HGPRT resulting in cell death. 
Only cells lacking this enzyme will survive thioguanine selection. Selection of
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HGPRT deficient cells is relatively easy since the enzyme is coded for by a gene on 
the X chromosome. Mammalian cells posses only one active X chromosome and 
therefore only a single mutation is needed to result in total loss of the enzyme. TK 
deficient mutants are much more difficult to select since two simultaneous rare 
events are required.
In order to express a differentiated cell function the two parental cells 
should be at a similar stage of differentiation. The fusion of unlike cells frequently 
results in the extinction of differentiated function (Ringertz & Savage. 1976). 
Antibody secretion is only maintained if normal antibody-secreting cells are fused 
with myeloma cells. The choice of fusion partners is of key importance. Ideally this 
should be from the same species and of the same basic cell type. Figure 1.2 shows 
an outline of the basic procedure for monoclonal antibody production.
1.3.3 Choice of Cells for Fusion
The choice of myeloma cell line for culture and animal for immunisation are 
two interdependent variables. Stable antibody secreting hybrids are generally not 
produced from fusions between cells of different species due to preferential 
chromosome loss from one or other of the parent cells. The range of possibilities is 
therefore limited by the availability of myeloma cell lines. The myeloma cell lines 
of established value were all derived from Balb/c mice or Lou rats (Galfre and 
Milstein, 1981; Reading, 1982). Some myeloma cell lines secrete their own 
immunoglobulin and continue to secrete this in hybrid cells where the myeloma and 
lymphocyte heavy and light chains are randomly assembled. The resultant secreted 
antibodies will therefore contain only a small proportion of the original lymphocyte 
antibody. Myeloma cell line variants which secrete only light chains and in some 
cases no immunoglobulin at all have also been isolated (Kohler et al, 1976; 
Kearney et al, 1979). Such cell lines are to be preferred for monoclonal antibody 
production for immunoassay purposes reducing the need later for extensive
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Figure 1.2 Procedure for the production of monoclonal antibodies.
purification.
Attempts at heterogeneous fusions between standard myeloma cell lines and 
lymphocytes of different species have been reported. Some success has been 
achieved from fusions between rat and mouse cells (Galfre et al,1977) and stable 
hybrids between mouse myeloma and human lymphocytes have been described 
(Schlom et al, 1980; Valente et al, 1982).
The most important factor determining the choice of animal for 
immunisation is the relative responsiveness to a given antigen, and for the difficult 
antigens it may be necessary to attempt immunisations of several strains of both 
mice and rats (Goding, 1980). It is also an advantage to be able to use myeloma 
cells and lymphocytes from the same inbred strain to facilitate the subsequent 
growth of hybrid cells in vivo in this strain. Inter-strain hybrids can only be grown 
as tumours in the corresponding FI hybrid animals. Inter-species hybrids are more 
problematical and in vivo growth needs to be in athymic (nude) mice or rats 
(Noeman et al, 1982).
It is usual to use the spleen as the source of lymphocytes for fusion when 
working with rats or mice, however, other cells e.g. lymph nodes may be used.
1.3.4 Immunisation
The potential yield of monoclonal antibodies is directly related to the 
immune response in vivo and the properties of the monoclonal antibodies will 
reflect those detected in the immunised animal. Immunisation strategy reported in 
monoclonal antibody production has the same mixture of serious study, anecdote 
and prejudice which has been described for conventional antiserum production. The 
initial immunisation is generally given subcutaneously or intraperitoneally using an 
emulsion of microgram quantities of antigen in Freund's complete adjuvant. One or 
more boosts emulsified in Freund's incomplete adjuvant may be given at intervals 
of a few weeks. The final boost is given intraperitoneally or intravenously in saline
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three to four days prior to fusion. The timing of the final boost is thought to be 
critical (Oi et al, 1978).
To increase the chances of one good responder it is worth immunising as 
many animals including different strains as the available antigen permits. 
Immunogen purity is not particularly critical since screening of antibodies and 
cloning strategies isolate products of interest. However the way in which antigen is 
presented may influence the characteristics of monoclonal antibodies subsequently 
produced. Attention must be paid to the chemistry of conjugation to carrier proteins 
to avoid masking important structural groups.
1.3.5. Fusion Protocol
While the fusion event is central to the production of hybridomas it 
represents only a very small part of the total effort required. An important factor 
determining success at this stage is that both parental cells should be in the best 
possible condition. Myeloma cells should be in an exponential growth phase and 
lymphocytes appropriately stimulated. The two cells types are mixed, washed and 
centrifuged into a pellet. The fusogen is then slowly added and mixed with the cells. 
The fusion process is terminated by dilution of the fusogen/cell mixture.
Polyethylene glycol is almost universally used as the fusogen. Individual 
batches of polyethylene glycol vary considerably in their toxicity. Typical 
concentrations of PEG range from 30% to 50%. Below 30% fusion frequency is low 
and above 50% toxicity becomes acute. Precise cell numbers/ratios, temperature 
and PEG concentration do not appear to be critical as a number of different 
protocols have been described and applied successfully (Galfre et al, 1977; Gefter 
et al, 1977; Oi et al, 1978).
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1.3.6 Hybrid Growth and Cloning
Fusion products are grown in medium containing HAT to selectively kill 
unfused myeloma cells. Unfused lymphocytes will not survive in culture for more 
than a few days.
Amongst the hybrid cells there will be a great variation in growth rates. 
Cells which grow fastest will rapidly dominate the culture numerically. Following 
fusion hybrids are unstable and prone to rapid loss of chromosomes. Since plasma 
cells may devote up to half their total protein synthesis to immunoglobulin a cell 
which sheds this burden is likely to grow faster. Thus there will be a strong 
tendency for cultures to be overgrown by non-secreting variants. To overcome this 
problem many workers have adopted the approach of distributing the products of 
fusion into a large number of small wells such that on average only one hybridoma 
clone grows in each (Oi & Herznberg, 1980). Following the initial growth phase at 
least two cloning steps should be performed to ensure that a monoclonal cell line is 
obtained. There are two main cloning techniques, that of limiting dilution or cloning 
on soft agar. The former is more widely used.
Cloning by limiting dilution is based on the Poisson distribution f(0)=e- ^  
where f(0 ) is the fraction of wells with no growth and X is the average number of 
clones per well. If X=l, then f(0)=37, ie, if at least 37% of wells show no growth 
then the probability is that those that do show growth contain true monoclonal 
hybridomas (Goding, 1980).
Hybrid cells in particular seem to be very intolerant of dilution. Early 
growth at low hybrid cell density is much improved by the presence of other cells as 
"feeders" (Coffino et al, 1972; Lernhardt et al, 1978). Most commonly peritoneal 
macrophages are used for this purpose though the use of thymocytes and normal 
spleen cells has been described (Hengartner et al, 1978; Oi & Herzenberg, 1980; 
Levy et al, 1978).
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1.3.7 Expansion of Cloned Hybridomas
Cloned hybridomas can either be grown in vitro producing antibody in 
culture supernatant or in vivo producing antibody in ascitic fluid. Typically antibody 
concentrations that can be achieved in culture supernatants are 10-100 pg/ml. In 
contrast IgG levels in ascitic fluid are frequently 3-15 mg/ml.
The production of ascites may be favoured by intraperitoneally injecting 
recipient mice with mineral oils, usually 2,6,10,14-tetramethylpentadecane, one 
week prior to the injection of cells (Hoogenraad et al, 1983). The growth of tumours 
often results in ascitic fluid volumes of 5 ml or more. Sequential taps of fluid may 
be taken from individual animals.
1.3.8 Screening Assays
The assays used for both the evaluation of serum in the immunised animal 
and screening of the fusion products should be as similar as possible to the type of 
assay in which the monoclonal antibody will ultimately be used (Haaijman et al, 
1984). Apart from this the chosen assay should be sensitive enough to detect the 
concentrations of antibody found in culture supernatants (<1 pg/ml). It should also 
be simple and rapid such that large numbers of samples can be handled at one time.
When fusions yield large numbers of positive hybrids it may be necessary to 
prioritise antibody characteristics requirements perhaps selecting on the basis of 
specificity rather than avidity.
When designing assay formats it should be remembered that coupling an 
antigen to solid-phase or labelling with an enzyme or radioisotope may alter, 
destroy or make inaccessible particular epitopes. This may lead to the preferential 
selection of antibodies with specificities other than those desired.
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1.4 IMMUNOASSAY METHODOLOGY
1.4.1 Introduction
The term "immunoassay" is used to describe the general technique wherein 
the substance of which the concentration in a biological fluid is to be measured (the 
analyte) is caused to react with a specific antibody directed against it, the analyte 
concentration being deduced by observation of the products of the binding reaction 
between them. The distinguishing feature is the use of an antibody as the essential 
"analytical reagent".
The particular usefulness of antibodies in this context principally derives 
from three characteristics 1) their high "structural specificity", i.e. their ability to 
recognise and bind to molecules of a particular molecular structure: 2) the relative 
ease with which antibodies of a defined structural specificity can be produced, 
originally by conventional immunisation procedures and more recently by in vitro 
hybridisation and selection techniques: 3) their generally high binding affinities 
which implies that they can be employed at low concentration to measure analytes 
likewise at low concentration.
These properties form the basis of the ubiquitous use of immunoassay 
procedures throughout biomedical science for the measurement of substances of 
biological importance.
It was in 1960 that two independent papers first described immunoassay 
techniques suitable for use in the clinical laboratory. While Yalow and Berson 
(1960) received the credit for the first description of the "radioimmunoassay" it was 
Ekins (1960) with his "saturation analysis" for thyroxine who first appreciated the 
wider potential of the technique.
The basic principle underlying immunoassay techniques is the Law of Mass
Action.
This can be represented by the equation:-
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ka
Ag + Ab <-----------------> AgAb
kd
where ka and kd are the association and dissociation constants respectively. The
equilibrium constant K can then be expressed as
ka [AgAb]
K = ------------= ----------------------
kd [Ag][Ab]
where [Ag], [Ab] and [AgAb] represent the concentrations of free and complexed
antigen and antibody in the final equilibrium mixture (Ekins, 1974).
1.4.2. Saturation Assays (Radioimmunoassay)
A fixed but limiting amount of antibody (Ab) is reacted with a fixed quantity 
of radioactively labelled antigen (Ag*) and a variable amount of antigen (Ag) 
(standard or unknown sample). At equilibrium, the binding sites are saturated with 
Ag* and Ag in proportion to their relative concentrations in the assay tube. The 
antibody bound and unbound (free) forms of antigen are separated and the amount 
of labelled Ag present in the bound fraction plotted as a function of the dose of 
antigen present. The concentration of Ag in an unknown sample may be read off a 
calibration (dose response) curve. This principle is illustrated in Figure 1.3. These 
assays are often referred to as "competitive" because of the competition between 
Ag and Ag* for the limited number of available antibody binding sites.
The sensitivity of an RIA is governed by four factors (Ekins, 1981)
i) the equilibrium constant of the antigen-antibody interaction i.e. the 
avidity of the antiserum.
ii) the experimental error involved in the measurement of antibody-bound 
and free antigen.
iii) the specific activity of the labelled antigen.
iv) the misclassification of the bound and free antigen.
In practice (i) and (ii) impose the major constraints on assay sensitivity (Ekins,
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Figure 1.3 Principles of saturation analysis and a typical dose response curve
1981) while factor (iv) is a major cause of experimental imprecision and bias 
(Ratcliffe, 1983).
1.4.3. Imm unom etric Assay
The immunoradiometric assay (IRMA) was first described over twenty 
years ago (Miles & Hales, 1968a). This assay technique differs from 
radioimmunoassay in that it employs a labelled antibody rather than antigen, and 
requires the use of excess rather than limiting amounts of antibody. In the original 
assays antigen was incubated with excess labelled antibody such that at equilibrium, 
with a high avidity antibody, most of the antigen but only a percentage of the 
labelled antibody, reacts to form the bound fraction. Free labelled antibody was 
separated by addition of solid-phase coupled antigen. The amount of antibody 
bound to antigen (not coupled to solid-phase) is directly proportional to the amount 
of antigen present. The most widely used form of immunometric assay is the two- 
site or sandwich assay (Woodhead et a/,1974) (Figure 1.4). As the term "two-site" 
suggests two antibodies are employed each being directed to unique epitopes on the 
antigen. One antibody is labelled (with a radioisotope in the case of IRMA) and the 
other is covalently coupled to a solid phase. Excess radiolabelled antibody (Abl*) 
is reacted with antigen which partially fills the available binding sites. Separation 
of free radiolabelled antibody from antigen bound radiolabelled antibody is 
achieved by adding another solid phase coupled antibody (Ab2-SP) which 
recognises and binds to a different antigenic determinant on the antigen molecule. 
The quantity of the label associated with the solid phase is directly proportional to 
the concentration of antigen in the assay tube through the formation of the *A bl- 
Ag-Ab2-SP "sandwich".
The theoretical and practical advantages of immunometric assays over 
competitive immunoassays have been amply documented (Miles and Hales, 1968a; 
Woodhead et al, 1974; Ekins, 1981; Hunter and Budd, 1981; Hunter et al, 1983).
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Figure 1.4 Principle of immunometric analysis and a typical dose response curve.
These include improvement in speed, increased sensitivity, wider working range, 
and greater specificity for intact biologically active molecules. Another factor in 
favour of the immunometric assay is the lack of dependence on purification and 
labelling of antigen, which may alter its immunoreactivity. Labelled polyclonal 
antibodies have found relatively restricted application in immunometric assays. 
This is because such assays consume large amounts of antibodies as excess 
reagents. Also antibodies must be purified from the bulk of serum immunoglobulin, 
of which it may constitute as little as 1% ,for labelling to high specific activity. 
Purification is achieved by specific adsorption to and elution from immobilised 
antigen (Hales and Woodhead, 1980). The elution of bound antibody, usually at low 
pH, may damage its reactivity or fail to recover the fraction with the highest avidity.
It is obvious that the properties of monoclonal antibodies are particularly 
suited to application in immunometric assays, and indeed overcome all the major 
problems associated with conventional antisera. Monoclonal antibodies for multiple 
distinct epitopes on a given antigen may be produced in large quantities and are 
easily purified. Antibodies of only moderate affinity may be used in sensitive 
immunometric assays with detection limits up to two orders of magnitude greater 
than can be achieved in competitive immunoassays with the same antibody 
(Buchegger et al, 1981; Weeks et al, 1981; Bosch et al, 1982; Van den Berg et al, 
1982; Hunter et al, 1983).
1.4.4 Alternatives to Radioisotopes as Label in Immunometric Assays
The function of a label in an immunoassay is to act as a marker of the 
relative distribution of antigen (saturation analysis) or antibody (immunometric 
analysis) between bound and free fractions. The only constraint imposed on the 
label is that it should not interfere with the antigen-antibody reaction. Consequently 
many such labels have been tried including i) enzymes or their substrates or 
cofactors ii) luminescent compounds (either fluorescent or chemiluminescent).
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The main potential of using an enzyme as a label is the amplification of 
signal effected by the enzyme acting on several substrate molecules. Many 
techniques have become established, EMIT (enzyme-multiplied immunoassay 
technique) and ELISA (enzyme-linked immunosorbent assay) having proved to be 
of particular value. ELISA utilises the two-site immunometric principle and has 
been developed to give assays sensitivities comparable with IRMA eg. Dako 
Diagnostics Ltd. amplified enzyme immunoassay. The principle of this assay is 
illustrated in Figure 1.5 .
Until recently fluorescent immunoassay was only practicable for analytes 
present in concentrations >1 0 " 8  M because of high and variable background 
fluorescence. The most promising development in this area is time-resolved 
fluoresence immunoassay as illustrated by the 'DELFIA' (dissociation-enhanced 
lanthanide fluoroimmunoassay) system marketed by Pharmacia-Wallac. Two 
approaches have been used to reduce background fluorescence and so increase 
sensitivity. Europium chelates have been used as the fluorophore. These have a 
large Stokes shift (difference in wavelength between incident and emitted light) and 
a relatively long lived fluoresence. Pharmacia-Wallac have also developed a 
fluorimeter which delays the measurement of emitted light by 400ms during which 
time non-specific background fluoresence will have largely disappeared (Soini & 
Hemmila, 1979). The principle of this method is illustrated in Figure 1.6 .
Chemiluminescent or bioluminescent molecules have been used in 
immunological reactions either directly as labels or indirectly in the quantitation by 
lnminesence of enzyme or co-factor labelled antigens or antibodies.
Chemiluminescence is the light emitted as a consequence of the de­
excitation of a reactant or a product of a particular chemical reaction. One 
disadvantage of these techniques is that the chemical reaction can only take place 
once ie. the assay cannot be recounted.
The original work in chemiluminescence immunoassay was based on the
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Figure 1.5 The principle of the Dako amplified enzyme immunoassay
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Figure 1.6 Principle of time-resolved fluorescence
luminol family of labels. Both homogeneous and separation assays for haptens 
based on the saturation analysis principle have been described (Collins et al, 1983). 
Figure 1.7 shows a schematic representation of the products obtained on the 
oxidation of luminol under basic conditions. Recently, aryl acridinium esters have 
received considerable attention as an alternative to luminol derivatives as labels in 
chemiluminescent assays. Use of acridinium esters in assays based on the two-site 
principle have produced some of the most sensitive assays for peptide hormones yet 
reported (Weeks et al, 1984). The signal generation system for these assays is 
illustrated in Figure 1.8.
Another form of chemiluminescent assay combines the attributes of 
luminometric measurement with the signal amplification provided by the use of 
enzyme labels. Originating from the studies of Whitehead et al (1983), assays based 
on the use of antibodies labelled with horseradish peroxidase and luminescent 
substrates have recently been launched by Amerlite Diagnostics Limited. 
Enhancement of the luminescent yield of the peroxidase system may be achieved by 
the use of phenols (Thorpe et al, 1985), resulting in further signal amplification and 
an increase in assay sensitivity.
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Figure 1.8 The chemiluminescent reaction of the acridinium ester 
p-carboxyphenyl-N, 10-methyI-9-carboxylate bromide.
1.5 OBJECTIVES
The objectives of this project were
1. To introduce into the Department of Pathological Biochemistry techniques 
for the production of monoclonal antibodies to a variety of peptide and protein 
hormones.
2. To select antibodies with suitable avidity and specificity for use in 
immunoassays of peptide hormones.
3. Where possible to isolate two complementary antibodies in order to develop 
two-site immunometric assays.
4 To validate these assays both analytically and clinically.
5 To compare and contrast the strategies tactics and outcomes when 
attempting to produce antibodies and develop assays to hormones of widely 
differing structural characteristics.
6 To evaluate the strategies adopt to rationalise future approaches.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Equipm ent
Items other than general laboratory ware are listed indicating suppliers.
Laminar flow cabinet
Water jacketed 37°C incubator
Transplate
NE 1600 gamma counter
Microflow Inter Med 
Scotlab
Northumbria Biologicals 
Nuclear Enterprises
FRAC 300 fraction collector and optical detector Pharmacia 
Ultrafiltration cell Amicon
Freeze dryer Edwards
Sonicator Fisons/MSE
HPLC system Beckman
2.1.2 Disposables
Culture flasks Corning
Culture plates 0.2 ml x 96 well Costar -  Northumbria
Biologicals
Culture plates 2.0 ml x 12 well Costar -  Northumbria
Biologicals
Non-sterile conical bottom 0.2 ml x 96 well plates Nunc
Sterile pipettes Sterilin
50 ml sterile conical tubes Corning
Cell freezing vial Sarstedt
Transplate cartridges Northumbria Biologicals
Sterile pasteur pipettes Alpha Laboratories
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0.2 [x filters Millipore
Sep-Pak cartridges Waters
Centricon ultrafiltration/concentration cartridges Amicon
2.1.3 Chemicals and Reagents
All chemicals used were analytical grade supplied by BDH, and synthetic 
peptides were supplied by Peninsula Laboratories, unless otherwise specified.
a) Chemical Reagents
Sodium (IMS 30) used in all iodination procedures was supplied
by Amersham International. All gels used in gel filtration procedures were supplied 
by Pharmacia Fine Chemicals. EDC (l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide HC1) and Iodogen were supplied by the Pierce Chemical Company. 
CDI (1,1'carbonydiimidazole) used for coupling antibodies to Sepharose particles 
and N-hydroxysulphosuccinimide used to enhance the EDC conjugation of peptides 
to carrier proteins were supplied by Sigma Chemical Company. N - 
bromosuccinimide and chloramine T used in ANF iodination procedures were also 
supplied by the Sigma Chemical Company. HPLC grade acetonitrile and acetic acid 
were supplied by Rathbum Chemicals. Dynospheres magnetic particles (XP6006) 
were obtained from Dyno Particles A S, Lillestrom, Norway. The proteinase 
inhibitor Trasylol used in ANF assay buffers was supplied by Bayer U.K. Ltd.
b) Biological Reagents
All antibodies and animal sera were obtained from the Scottish Antibody 
Production Unit unless otherwise indicated. Synthetic peptides PTH1-10, PTH77- 
84, ANF1-7 and ANF23-28 and their respective KLH conjugates were prepared 
and supplied by Cambridge Research Biologicals. Growth hormone for iodination 
was supplied by NIBSC and for immunisation was a gift from Dr S Lynch. Freunds
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complete and incomplete adjuvants were supplied by Difco Laboratories. Bovine 
serum albumin and bovine gamma globulin were purchased from the Sigma 
Chemical Company.
c) Tissue Culture Reagents
Murine myeloma cells (X63.Ag8.653) were supplied by Flow Laboratories 
and the rat myeloma cell line YB2/0 was a gift from Dr C. Milstein (MRC 
Cambridge). Pristane (2,6,10,14-tetramethypentadecane) was purchased from the 
Sigma Chemical Company. Dimethyl sulphoxide (DMSO) and polyethylene glycol 
1500 (PEG 1500) were supplied by BDH. All other reagents used in tissue culture 
work were obtained from Flow Laboratories.
2.1.4 Preparation of Buffers
Buffer 1 -  0.5M Phosphate Buffer
A — 178 g di-sodium hydrogen orthophosphate dihydrate dissolved 
in distilled water and made to a volume of 2  litre.
B —  39 g sodium di-hydrogen orthophosphate dissolved in distilled 
water and made to a volume of 500 ml.
Solution A titrated with B to pH 7.4.
Buffer 2 -  EPPS Buffer
25.23g EPPS -  ( 4 - [2 -  hydroxyethyl] -  1 -  piperazine -
propane sulphonic acid)
0.5g sodium azide
The above reagents were dissolved in distilled water and the pH 
adjusted to 8.0 with 4M sodium hydroxide. Tween-20 (2ml) was then 
added and the final volume adjusted to 1 litre with distilled water.
52
Buffer 3 -  Gel Filtration Column Elution Buffer
100ml 0.5M phosphate buffer (buffer 1)
5.0g bovine serum albumin
l.Og sodium azide
Dissolved in distilled water and made to 1 litre.
Buffer 4 -  GH Assay Buffer
995 ml EPPS buffer (buffer 2)
5.0 ml sheep serum
Prepared fresh weekly and stored at 4°C.
Buffer 5 -  PTH Assay Buffer
200  ml 0.5M phosphate buffer (buffer 1)
9.0 g sodium chloride
2.0  g sodium azide
18.6 g sodium EDTA
10.0  g bovine serum albumin (protease free) 
— ICN Biochemicals
2.0  ml Tween-20
The above reagents were dissolved in distilled water and the final 
volume adjusted to 1 litre by further addition of distilled water. 
Immediately prior to use 0.5 ml 30% w/v hydrogen peroxide was 
diluted to 100  ml with the above buffer.
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Buffer 6  -  ANF Assay Buffer
100 ml 0.5M phosphate buffer pH 7.4 
l.Og bovine serum albumin
9.0g sodium chloride
l.Og sodium azide
3.72g sodium EDTA
5x10^ KIU trasylol
The above were dissolved in distilled water and the volume made to 1 
litre.
Buffer 7 -  Acetate Buffer
A —  8.2 g of anhydrous sodium acetate dissolved in distilled water 
and made to 1 litre.
B —  5.7 ml of glacial acetic acid diluted to 1 litre with distilled 
water.
Solution B titrated with A to pH 4.0
Buffer 8 -  TAPS Buffer
24.3 g TAPS -  ( [ 2-hydroxy -  1, 1 -  bis (hydroxymethyl) -
ethyl] amino) -  1 -  propanesulphonic acid)
Dissolved in distilled water and adjusted to pH 8 .6 . Final volume was
adjusted to 1 litre with distilled water.
54
Buffer 9 -  Protein A Binding Buffer
56.3 g glycine
87.6 g sodium chloride
Dissolved in 450 ml distilled water. The pH was then adjusted to 9.0 
with 5M sodium hydroxide prior to making the volume to 500 ml with 
distilled water.
Buffer 10 -  Protein A Elution Buffers/Regeneration Buffer 
8.7 g citric acid dihydrate
Dissolved in 450 ml distilled water and the pH adjusted as required 
with 5M sodium hydroxide
2.1.5 Preparation of Standards
a) Growth Hormone
The contents of an ampoule of GH standard (IRP 66/217) were dissolved in 
0.5 ml of 0.05M phosphate buffer pH 7.4 containing 0.1% BSA. The solution was 
made volumetrically to 500 ml with 0.05M phosphate buffer containing 0.1% BSA 
to give a stock standard of 700000 mU/1. This material was aliquoted in 1 ml 
amounts and stored at -80°C. Working standards were prepared by appropriate 
dilution in assay buffers.
The working standards UK7 and UK8 supplied by EQAS were used 
according to the suppliers instructions.
b) Parathyroid Hormone
PTH(l-84) standards were prepared from synthetic PTH supplied by 
Peninsula Laboratories. The contents of a vial (20 ug) were dissolved in 2 ml 
0.05M barbitone buffer pH 8.6  containing 0.5% BSA. Aliquots (100 pi = 1 pg) 
were stored at -80°C  as a concentrated standard. Further dilution of 100 pi of
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concentrated standard to 10 ml with barbitone buffer produced a stock standard at a 
concentration of 10 ng/100 pi. This was also aliquoted (100 pi) and stored at -  
80°C
Working standards were prepared freshly for each assay. Stock standard 
(100  pi) was diluted 1/20  with equine serum and further dilutions, also in equine 
serum, were prepared producing working standards of 500, 250, 62.5, 15.6, 3.9 and 
0.98 pmol/1.
c) Atrial Natriuretic Factor
Atrial natriuretic factor standards were prepared from synthetic ANF 99- 
126 supplied by either Bachem or Peninsula Laboratories. Contents of vials were 
dissolved in 1 ml distilled water and then volumetrically made to 25 ml. Aliquots 
(0.5 ml) were stored at -80°C. Further dilutions to appropriate concentrations were 
made in ANF assay buffer when required. Met[0] ANF 99-126 standards were 
prepared in the same manner from material supplied by Peninsula Laboratories.
2.2 METHODS
2.2.1 Isolation of IgG Fractions of Antisera and Ascitic Fluids
The n-octanoic acid precipitation method of Steinbuch and Audran (1969) 
was used to prepare IgG fractions of antisera and ascitic fluids unless otherwise 
indicated.
Antisera or ascitic fluids (10 ml) were titrated to pH 5.0 with 0.1M acetic 
acid and 0.9 ml of a 91% solution of n-octanoic acid added dropwise while 
constantly stirring. Constant agitation was continued for 30 minutes prior to 
centrifugation at 1500g for 20 minutes. The supernatant was retained, and the 
precipitate washed with 20 ml of 0.1M sodium bicarbonate pH 8.0 by constant
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mixing for a further 30 minutes. Following re-centrifugation of the washed 
precipitate the supernatants were pooled and placed in an Amicon ultrafiltration cell 
fitted with a Diaflow PM10 filter, washed under pressure (15 psi) with 0.1M sodium 
bicarbonate to remove the n-octanoic acid, and then concentrated. The protein 
concentration of the recovered solution was then assayed.
2.2.2 Protein Estimation
Protein concentrations of IgG extracts were determined by the method of 
Schacterle and Pollack (1973), this method being a modification of that of Lowry et 
al (1951).
Reagents
a) Alkaline Copper Reagent
Sodium carbonate (lOg) was dissolved in 50 ml of 1M sodium hydroxide.Potassium 
tartrate (100 mg) and cupric sulphate (50 mg) were separately dissolved in 2 -3  ml 
of distilled water and then added to the sodium carbonate solution. The volume was 
then adjusted to 100  ml with distilled water.
b) Folin-Ciocalteau Reagent
Supplied by BDH was diluted 1:25 with distilled water prior to use.
c) Protein Standards
A stock solution was prepared by dissolving 50 mg of bovine serum albumin in 50 
ml of distilled water. Working standards were serial x2 dilutions of this stock in 
distilled water.
Method
Protein estimation were caried out in duplicate. Aliquots (200 pi) of standard or
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sample were mixed with 200  pi of alkaline copper reagent and incubated for 10 
minutes at ambient temperature. Dilute Folin-Ciocaltaeu reagent (1 ml) was then 
added, the tubes vortexed and placed in a water bath at 55°C for 5 minutes. Tubes 
were rapidly cooled by placing them in cold water for 2 minutes. Absorbance was 
measured at a wavelength of 650 nm in 10 mm glass cuvettes within 30 minutes. A 
standard curve was constmcted from which the sample concentration was 
determined.
2.2.3 Coupling of Antibodies to Sepharose Particles
Coupling of antibodies to Sepharose CL4B proceedes in two stages, 
activation and coupling.
Activation
Sepharose particles were activated essentially by the method of Chapman and 
Ratcliffe (1981) described for cellulose particles.
The particle concentration of a suspension of Sepharose CL4B was adjusted 
to 2 0  mg/ml by allowing a gel suspension to settle in a measuring cylinder 
overnight, removing the supernatant and adjusting the total volume with distilled 
water to twice that of the settled gel. Calibrated gel (200 ml) was placed in a 37 p 
porosity sintered glass Buchner funnel and dehydrated by successive washes under 
negative pressure with 250 ml of distilled water, 30%, 50% and 70% v/v acetone in 
distilled water, and 100% acetone. Care was taken not to allow the gel to dry.
The dehydrated gel was then transfered to a glass conical flask and the 
volume adjusted to 200 ml with acetone. Carbonyldiimidazole ( 4.87g) was then 
added. The flask was sealed with a ground glass stopper and gently stirred for 60 
minutes. After transferring the gel back to the Buchner funnel rehydration was 
accomplished by reversing the dehydration procedure. The final rehydration wash 
was with EPPS buffer pH 8.0 after which the activated gel was transferred to a 
calibrated poly-carbonate bottle and the volume adjusted to 20 0  ml.
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Coupling
Coupling is performed immediately after gel activation. Purified IgG (120 mg) was 
added to the activated gel and mixed for 18 hours at ambient temperature. IgG 
remaining in solution was recovered in the supernatant following centrifugation for 
10 minutes at lOOOg. This was then re-concentrated in an ultrafiltration cell for 
future use. The recovered gel was then subjected to centrifugation/wash cycles with 
2 x 200 ml of 0.5M sodium bicarbonate pH 8.0 and 2 x 200 ml of 0.1M acetate 
buffer pH 4.0. Washing was achieved by rotating for 20, 20, and 60 minutes then 18 
hours respectively with centrifugation and aspiration of supernatants to change 
buffers. Finally the gel was washed with 0.9% sodium chloride and then EPPS 
buffer pH 8.0 containing 0.1% sodium azide and 0.1% bovine serum albumin. The 
final volume was adjusted to 200  ml to give a particle concentration of 20  mg/ml. 
Gel was stored a 4°C until required.
Batch preparations of different sizes were accomplished by proportional alterations 
of volumes.
2.2.4 Radioiodination Methods
Antigen and antibody iodinations were performed by the solid-phase 
lactoperoxidase method of Karonen et al (1975) unless otherwise indicated. The 
chloramine T ( Hunter and Greenwood, 1962), Iodogen (Fraker and Speck, 1978) 
and N-bromosuccinimide (Reay, 1982) methods were used to iodinated ANF (see 
Chapter 5).
Lactoperoxidase Method
Antigens 2-5 pg or antibodies 20 pg in 10-20 pi of either distilled water or 0.5M 
phosphate buffer pH 7.4 were iodinated by the addition of the following:-
10 or 20 pi 0.5M phosphate buffer pH 7.4
10 pi solid-phase lactoperoxidase (locally prepared)
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5 or 10 pi sodium 12f>iodide (18.5 or 37 MBq)
10 ixl hydrogen peroxide (30% w/v stock diluted 1/20000 with
distilled water)
The mixture was vortexed and incubated at ambient temperature for 15 minutes and 
the reaction terminated by dilution with 200 pi of buffer 3 or 80 pi of distilled water 
followed by centrifugation at 500g for 2 minutes.
Chloramine T Method
20 pi 0.5M phosphate buffer pH 7.4
20  pi peptide 5pg
10  pi sodium l^ iod ide  (37  MBq)
10 pi chloramine T (1 mg/ml) in 0.05M phosphate buffer
Contents were mixed and incubated for 30 seconds 
The reaction was terminated by the addition of 10 pi sodium metabisulphite (2 
mg/ml in 0.05M phosphate buffer) and further diluted with 80 pi of distilled water.
Iodogen Method
Iodogen (l,3,4,6-tetrachloro-3a,6a-diphenylglycouril) (25mg) was dissolved in 
100 ml of dichloromethane. Aliquots (50 pi _ 5 pg iocbgen/tube) were dispensed 
into conical bottomed polypropylene tubes and allowed to dry in air. These tubes 
were then capped and stored in a dessicator at -20°C until required.
5 pg Iodogen
20 pi 0.5M phosphate buffer pH 7.4
2 0  pi peptide 5pg
10 pi sodium 125^(1^  (37  MBq)
Contents were mixed and incubated for 10 minues 
The reaction was terminated by the addition of 100 nl of distilled water and
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transferring the reaction mixture to a clean tube.
N-Bromsuccinimide Method
N-bromosuccinimide (0.01M) was freshly prepared by dissolving 0.178 g in 
distilled water and adjusting the final volume to 100 ml. This stock solution was 
further diluted 1/100  for use in the following procedure.
20 pi 0.5M phosphate buffer pH 7.4
20 pi peptide 5 pg
1 0  pi sodium l^ io d id e  ( 3 7  MBq)
10 pi N-bromOvSuccinimide
Contents were mixed and incubated for 15 seconds 
The reaction was terminated by the addition o f 10 pi sodium metabisulphite (2  
m g/m l in distilled water) and further diluted with 80 pi o f  distilled water
2.2.5 Preparation of Conjugates for use as Immunogens
a) Parathyroid Hormone
PTH(l-34) and PTH(53-84) peptides were coupled to bovine serum 
albumin by the carbodiimide method of Orth (1979). PTH(l-lO) with and 
additional C-terminal cysteine residue and PTH(76-84) with an additional N - 
terminal cysteine residue were custom synthesised and conjugated to keyhole 
limpet haemocyanin by Cambridge Research Biochemicals. A bis-diazotised 
tolidine linkage was used producing, respectively, C and N terminally bound 
peptides.
b) Atrial Natriuretic Factor
ANF 99-105 and ANF 121-126 were custom synthesised and conjugated to 
keyhole limpet haemocyanin by Cambridge Research Biochemicals. ANF 99-105 
was C-teminally linked and ANF 121-126 was N-terminally linked using a N - 
maleimidobenzyl-N'-hydroxysuccinimide ester.
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Albumin conjugates of ANF 99-126, ANF 99-105, ANF 121-126, ANF 
99-109 and ANF 111-126 were prepared by the method of Staros et al (1986). The 
utility of carbodiimide conjugation methods has been limited by low coupling 
yields. Staros et al (1986) have reported the use of N-hydroxysulphosuccinimide as 
an enhancing agent of water soluable carbodiimide-mediated coupling reactions 
claiming a ten fold increase in efficiency. EDC, l-e th y l-3 -(3  
dimethylaminopropyl) carbodiimide hydrochloride and N - 
hyroxysulphosuccinimide were supplied by Pierce. Crystalline bovine serum 
albumin (fraction V) was supplied by Sigma.
Briefly, 32.5 mg of BSA and 7.75 mg N-hydroxysulphosuccinimide (HSS) 
were dissolved in 1 ml of distilled water. EDC (178 mg) was also dissolved in a 
further 1 ml of distilled water. Peptide (0.5 mg) was weighed into a tube and 
dissolved in 125 pi of distilled water, 50 pi of BSA/HSS solution, 25 pi of EDC and 
25 pi of 1^25ANF 99-126 (50000 cpm) were added. Following incubation at 
ambient temperature for 90 minutes the mixture was applied to a Sephadex G50 gel 
filtration column and eluted with 0.05M phosphate buffer pH7.4. The absorbance of 
the column eluant at 214 nm was continuously monitored and 1 ml fractions were 
collected. The radioactivity in each tube was also assessed and used to calculate the 
coupling ratio.
2.2.6 Immunisations
Conjugates/peptides in saline (0.2 ml) were emulsified by sonication in an 
ice bath with 0.6 ml of Freunds adjuvant (complete adjuvant for primary 
immunisations and incomplete adjuvant for subsequent immunisations). Mice were 
given intraperitoneal injections and rats multisite subcutaneous injections 
(Vaitukaitis et al, 1971) of 0.1 ml of emulsion using a 26g 0.5 inch hypodermic 
needle. Injection doses were calculated to be equivalent to between 5 and 20 pg of 
peptide. Secondary immunisations were at 2-3 week intervals following the
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primary. Three days prior to fusions donor mice were injected intravenously via the 
tail vein with 5 pg of peptide in 0.1 ml of sterile physiological saline. Rats were 
given this pre-fusion dose via the jugular vein.
2.2.7 Test Bleeds
Mice were anaesthetised with ether, the ventral tail vein punctured with a 
sterile 23g hypodermic needle and the exuding blood absorbed onto filter paper card 
to form a discrete spot. Mice were colour coded to aid identification. Blood spots 
were allowed to dry prior to a 6 mm disc being punched into a test tube containing
0.5 ml of 0.9% saline. This approximated to an initial dilution of 1/250 i.e. 0.002 ml 
serum/6mm disc. Bleeds were assessed for the presence of specific antibody as 
described in section 2.2.9. .
2.2.8 Monoclonal Antibody Production
Monoclonal antibodies were produced by the method of Kohler and Milstein 
(1975) with local adaptions. Myeloma cell lines used in hybridisation experiments 
were either murine X63.Ag 8.653 cells (Kearney et al, 1979) or rat YB2/0 cells 
(Kilmartin et al, 1982).
a) Culture of Myeloma Cells
i) Culture Medium
100 ml RPMI 1640 (Rothwell Park Memorial Institute) buffered with 20 mmol/1 
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid).
10  ml heat inactivated foetal bovine serum
1 ml glutamine (200  mmol/1)
2 ml penicillin/streptomycin (5000 U/ml and 5 mg/ml respectively)
1 ml fungizone (250 pg/ml)
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ii) Maintenance
Cells were counted daily using a Neubauer haemocytometer and cell density was 
maintained between 2.5 x 10^ cells/ml and 1.2 x 10^ cells/ml by appropriate 
dilution in fresh media. Viability was assessed using a trypan blue dye exclusion 
method. When in logarithmic growth doubling time was approximately 18 hours. 
The number of cells maintained was expanded in the week leading up to a 
hybridisation experiment so that on the day of the experiment 150 x 10^ cell 
were available. Immediately prior to hybriisation experiments these cells were 
washed three times with RPMI 1640 and three 5 ml aliquots in RPMI 1640 
prepared, each containing 50 x 10^ cells.
b) Preparation of Mouse Peritoneal Macrophages
Mouse peritoneal macrophages were used as feeder cells to support the growth 
of hybrids at low cell density. Three balb/c mice were killed and dissected to 
reveal the peritoneum. Syringes fitted with 19 gauge needles were used to inject 
5 ml of RPMI 1640 into their abdominal cavites. The abdomen was massaged to 
suspend peritoneal cells and the RPMI 1640 withdrawn into the syringe. 
Washing were pooled into a 50ml sterile conical tube and centrifuged for 5 
minutes at 500g. The supernatant was decanted and the cells re-suspended in 
RPMI 1640 and counted. Cells were then diluted in hydrid culture medium 
(myeloma cell culture medium plus a futher 10 ml of foetal bovine serum) to a 
density of 30000 cells/ml and distributed to culture wells or flasks as 
appropriate.
c) Preparation of Spleen Lymphocytes
Immediately prior to hybridisation experiments the previously selected mouse 
was killed and the spleen removed using aseptic techniques and placed in a
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sterile tube containing 5 ml RPMI 1640. Futher manipulations were conducted in 
a laminar flow cabinet. The spleen was placed in a sterile petri dish and fatty 
tissue was removed. The spleen was then cut in half and the cells teased from the 
capsule using scalpel blades. The contents of the dish were transferred to a tube 
and the large fragments of tissue allowed to settle. The suspended cells were 
transferred to another tube and centrifuged for 5 minutes at 500g. The 
supernatant was then decanted and the cells resuspended in 15 ml RPMI 1640. 
An aliquot (100 pi) was taken, the red cells lysed, and spleen lymphocytes 
counted. Three 5ml aliquots of suspended cells were prepared each containing 
approximately 50 x 10^ cells.
d) Preparation of Polyethylene Glycol 1500 (PEG)
Polyethylene glycol 1500 (10 g) was weighed into a measuring cylinder and 5ml 
of RPMI 1640 added. The cylinder was then placed in a 50oC water bath until 
the PEG liquified. The pH was adjusted to approximately 7.0 with 0.1M sodium 
hydroxide, the phenol red in the RPMI 1640 acting as the indicator. The volume 
was then made to 20 ml with futher pre-warmed RPMI giving a 50% w/v 
solution. The PEG solution was then sterilised by filtration through a 0.2 p filter.
e) Hybridisation Protocol
The day prior to a hybridisatiom experiments peritoneal macrophages were 
harvested, suspended in hybrid culture medium (myeloma cell culture medium 
plus a further 10 ml of foetal bovine serum) and dispenced into fifteen 96 x 0 .2  
ml well sterile flat bottomed microtitre plates (100 pl/well = 3000 cells/well). 
The aliquots of prepared spleen cells (50x106) and myeloma cells (50x106) were 
mixed and centrifuged at 500g for 10 minutes. The supernatant was decanted and 
the universal bottle containing the cell pellet placed in a beaker of water at 37°C. 
Pre-warmed (37°C) 50% w/v PEG (0.8 ml) was added dropwise over one
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minute while gently agitating the cells. After a further minute of mixing 10 ml of 
pre-warmed RPMI 1640 was added over five minutes, gradually increasing the 
rateof dilution to avoid osmotic shock. Cells were then centrifuged at 500g for 
ten minutes and washed with 2x20 ml RPMI 1640 finally being resuspended in 
60 ml of pre-warmed culture medium supplemented with a further 10  ml of 
inactivated foetal calf serum and HAT (hypoxanthine/aminopterin/thymidine -  
100, 0.4 and 16 pmol/1, respectively). The hybridisation products were then 
transferred, using a Transplate 96 (Northumbria Biologicals) into 5 96x0.2 ml 
well microtitre plates (0.1 ml/well) pre seeded with peritoneal macrophages. All 
plates were sealed with sellotape and incubated at 37°C for 10-14 days before 
examination for the presence of growing hybrids. This procedure was repeated 
for each of the three aliquots of myeloma and spleen cells.
2.2.9 Screening Assays
All wells containing growing hybrids were screened for the presence of 
specific antibody by radioimmunoassay. Approximately 0.15 ml of culture 
supernatant was removed aseptically from each well, fresh medium replaced and 
the plate returned to the incubator.
Cell supernatants (50 pi) were incubated overnight at ambient temperature 
with 100 pi (20000 cpm) of appropriate l!25 labelled antigen. Sepharose coupled 
sheep anti-mouse y-globulin (lmg/0 .2  ml) was added and the tubes incubated on 
an orbital shaker at 300 rpm for 60 minutes. The Sepharose particles were then 
washed with 3x2 ml 0.9% sodium chloride containing 0.2% Tween 20 (v/v) and 
following the final centrifugation and aspiration the radioactivity in the bound 
fraction was counted. Bound radioactivity was expressed as a percentage of the 
total radioactivity added. Cell supernatants giving binding greater than 10% were 
further studied to assess antibody avidity by displacement analysis.
Cell supernatants were diluted 1:3, 1:9, 1:27 etc. and analysed in the
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presence of a displacement dose of appropriate antigen (GH = 50 mU/1, PTH 1-84 
= 500 pmol/1). Displacement was calculated (B0-Bd/B0xl00% where BO = binding 
in the absence of antigen and Bd = binding in the presence of antigen) at each 
dilution with those wells giving the greatest displacement, therefore highest avidity, 
being selected for cloning.
2.2.10 Cloning and Propagation
Following identification of wells containing cells secreting antibody of 
interest these cells were diluted to 1.5 ml in culture medium in a well of a 12x2 ml 
plate. This cell suspension was then dispensed into the first column (8  wells -  100 
pl/well) of a 96x0.2ml plate which had previously been seeded with peritoneal 
macrophages (100 pl/well approx 3000 cells) as previously described. The cell 
suspensions in the wells of the first column were then double diluted into the next 
column and this dilution repeated across the twelve columns of the plate. Culture 
medium was then added to each well to bring the volume to 0.2  ml, the plate was 
then sealed and placed in a 37oC incubator. Cell growth was monitored daily and 
screening of gfrowing hybrids undertaken after approximately fourteen days.
The cell suspension remaining in the 2 ml well was supplemented with 
media containing peritoneal macrophages and also placed in the incubator. When 
the cell density expanded sufficiently these cells were transferredto a 25 ml flask in 
5 ml of macrophage supplemented media and following expansion a 75 ml flask. 
When sufficient cells were generated and maintained in logarithmic growth with a 
viability, as measured by dye exclusion, of >90% they were frozen and stored in 
liquid nitrogen. This provided a back up should cloning fail or the cloning plate be 
contaminated.
Screening of cloning plates was performed as described in section 2.2.9. . 
The selection criteria for further cloning were antibody characteristics and highest 
initial dilution (i.e. furthest to the right on the plate while maintaining the presence
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of antibody secreting cells). Two or three wells from each initial cloning plate were 
selected for further cloning. Each of these were also propagated in 2 ml wells and 
flasks for back up purposes.
Following the second cloning procedure and appropriate screening selected 
cells were expanded in flasks for both freezing and in vivo propagation.
2.2.11 Freezing and Recovery of Cells
All cell lines were stored frozen in liquid nitrogen. Cells in culture were 
centrifuged at 500g for 10 minutes the culture medium discarded and replaced with 
10% v/v dime thy lsulphoxide in foetal calf serum previously coled to 4°C. This 
solution was initially added dropwise with gentle agitation of the cell pellet, to give 
a final concentration of 3-5  x l0 ° cells/ml. Aliquots (1 ml) were transferred to 
cryovials were placed in a polystyrene box and froze slowly to -80°C. After sixteen 
hours vials were transferred to liquid nitrogen for long term storage.
Recovery of cells was achieved by rapid thawing at 37°C. Cells were 
diluted in 20 ml RPMI 1640 and centrifuged at 500g for ten minutes. The cell pellet 
was then resuspended in 1 ml of culture medium and transferred to a 25 ml flask 
containing 4 ml of medium supplemented with macrophage feeder cells.
2.2.12 Propagation of Hybridomas in vivo
Mice to be used for in vivo propagation of hybridomas were primed by the 
intraperitoneal injection of 0.5 ml pristane (2,6,10,14-tetramethyl pentadecane) at 
least one week before the intraperitoneal injection of 2x10^ hybridoma cells. 
Hybridoma cells were prepared for injection by centrifugation, washing and finally 
resuspending in RPMI 1640 to a cell concentration of 4xl0^/ml. Following 
innoculation mice were observed daily for evidence of abdominal distention. When 
present ascitic fluid was collected, following anaesthetisation with diethyl ether, by 
puncturing the abdomen with a 19g hypodermic needle and allowing the fluid to
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drain under gravity. The fluid was clarified by centrifugation and stored at -20°C  
until required. In general this procedure was repeated every 2-3  days throughout 
the remaining life-span of the animals. Ascitic fluid obtained in this way was 
further purified for assay use by either the method described in section 2 .2.1  or that 
described in section 6.3.1. .
2.2.13 Isotyping of Monoclonal Antibodies
Mouse monoclonal antibody typing kits supplied by Serotec were used for 
antibody immunoglobulin class and subclass determination.
The immunodiffusion plate was removed from its sealed sleeve, opened and 
allowed to equilibrate to ambient temperature so that condensation could evaporate 
from the gel surface. Test culture supernatant (75 pi -  containing 1-20 mg/1 
antibody) was placed in the large central well of one of the rosettes. The six 
antisera supplied, directed against directed against the mouse immunoglobulin 
classes and subclasses IgGl, IgG2a, IgG2b, IgA and IgM, were individually 
transferred (100 pi) to the six outer wells of the same rosette. The plate was then 
tightly closed and stored flat at ambient temperature for 24-48 hours. After this 
time the immunoprecipitate relevant to the immunoglobulin specificity was visible.
2.2.14 Data Reduction and E rro r Analysis Methods
All dose response curves were prepared using a mass action model (Malan 
et al, 1978) data reduction program on an Apple IIGS microcomputer. This WHO 
program was supplied by Dr P. Edwards, Middlesex Hospital, London. The 
program also calculated precision profiles as described by Ekins (Ekins & Edwards, 
1983). The basis of this computation is to obtain estimates of the error associated 
with each dose. The errors in the response (R) for a given dose (D) are assumed to 
be normally distributed around the mean value and this variation can be defined 
algebraically as :-
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SD of the response estimation (6 R)
SD of dose estimation (6D) = -----------------------------------------
slope of the dose response curve
6R
6D = --------
6R/6D
The slope and/or the error (R) changes with dose, implying that the observed 
6D will differ over the concentration range of interest. This changing relationship 
between 6 D and D is the precision profile.
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CHAPTER 3
GROWTH HORMONE : THE PRODUCTION OF A MONOCLONAL 
ANTIBODY AND ITS APPLICATION TO AN IMMUNORADIOMETRIC
ASSAY
SD of the response estimation (6 R)
SD of dose estimation (SD) = -----------------------------------------
slope of the dose response curve
SR
6D = --------
SR/6D
The slope and/or the error (R) changes with dose, implying that the observed 
SD will differ over the concentration range of interest. This changing relationship 
between SD and D is the precision profile.
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3.1. INTRODUCTION
3.1.1. S tructure of Growth Hormone
Human growth hormone is a globular protein having a molecular weight of 
22000 daltons. It consists of a single polypeptide chain of 191 amino acid residues 
and it has two disulphide bridges. These bridges are between residues 53 and 165, 
and 182 and 189 (Figure 3.1). Little is known of the tertiary structure of growth 
hormone mainly because suitable crystals for x-ray diffraction studies have not yet 
been successfully prepared (Philips, 1987).
3.1.2. Biosynthesis of Growth Hormone
Biosynthesis of growth hormone takes place in the pituitary somatotrophs. 
These acidophilic cells are located predominantly in the lateral wings of the anterior 
pituitary and characterised by the presence of membrane bound secretory granules 
measuring 368 + 60 nm (SD) in diameter (Daughaday, 1985).
The genes involved in growth hormone biosynthesis are located on a long 
arm of chromosome 17 and are closely related to chorionic somatomammotrophin 
genes (Figure 3.2a). The growth hormone/chorionic somatomammotrophin gene 
family is composed of multiple copies of the growth hormone and chorionic 
somatomammotrophin genes, all of which are remarkably similar (Chawla et al, 
1983; Miller and Eberhardt, 1983). The extent of sequence homology in coding and 
non-coding regions is 90 -  95%. Each of the genes has five coding sequences 
(exons) separated by four intervening sequences (introns). The positions and 
lengths of these four introns are identical for all members of this gene family. The 
GH1 gene codes the authentic 22K growth hormone while the GH2 gene codes the 
20K variant. The 20K variant differs from 22K growth hormone by the internal 
deletion of 15 amino acid residues, residues 32-46 (Lewis et al, 1980; Denotto et 
al, 1981). A schematic representation of the transcription, processing and
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translation of the growth hormone genes is shown in Figure 3.2b.
Additional size and charge variants of growth hormone have been reported 
and these include two 24K variants, 45K dimers and forms with molecular weights 
>100000 (Chawla et at, 1983; Wright et al, 1974).
The existence of a short lived precursor comprised of an additional 
26 amino acids at the N-terminus has been described (Bancroft et al, 1976).
Growth hormone is the most abundant hormone in the human 
pituitary gland, the anterior lobe of which contains 5-10 mg stored in secretory 
granules (Daughaday, 1985).
3.1.3. Factors Controlling Plasma Growth Hormone Levels
Secretion from the anterior pituitary is primarily under the control of two 
hypothalamic peptides, growth hormone releasing hormone (GHRH) and 
somatostatin.
GHRH has been described variously as a 40, 44 and 37 amino acid peptide 
all of which were originally derived from pancreatic GHRH secreting tumours 
(Guillemin et al, 1982; Rivier et al, 1982). There remains some discussion as to the 
exact nature of hypothalamic GHRH.
Somatostatin can exist as 14 and 28 amino acid peptides both of which 
inhibit growth hormone secretion (Reichlin, 1985).
The secretion and or activity of GHRH and somatostatin are modulated by 
neurotransmitters, dopamine, noradrenaline, serotonin and enkephalin. A great 
number of metabolic, hormonal and pharmacological factors can effect growth 
hormone release by modifying the release of these neurotransmitters (Table 
3.1)(Daughaday, 1985). Growth hormone and insulin-like growth factor I (IGFI 
also known as somatomedin-C) concentrations also effect the release of 
somatostatin thus completing a classical feedback loop.
IGFI, a 70 amino acid, straight chain, basic peptide, may also act directly on
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Table 3.1
FACTORS
Neurogenic
Metabolic
Hormonal
INFLUENCING NORMAL GROW TH HORM ONE SECRETION
Augmentation Inhibition
1. Stages III and IV sleep 1. REM sleep
2. Stress ( traumatic, psycho­
genic, infectious, surgical)
2. Emotional Deprivation
3. a-Adrenergic agonists 3. a-Adrenergic antagonists
4. p-Adrenergic antagonists 4. p-Adrenergic agonists
5. L-dopa
1. Hypoglycaemia 1. Hyperglycaemia
2. Falling fatty acid concentration 2. Rising fatty acid concentra
3. Amino acids 3. Obesity
4. Uncontrolled diabetes
5. Uraemia
6 . Hepatic cirrhosis
1. GHRH 1. Somatostatin
2. Oestrogens 2. Hypothyroidism
3. Glucagon 3. Large doses of 
corticosteroids
4. Vasopressin
the pituitary to inhibit GHRH-stimulated secretion of growth hormone (Underwood 
and Judson, 1985).
3.1.4. Physiological Effects of Growth Hormone
For many years the actions of growth hormone appeared to be paradoxical, 
the growth promoting effects on muscle and skeletal tissue being insulin-like 
effects, while the diabetogenic effects on carbohydrate metabolism and lipolytic 
effects on adipose tissue were antagonistic to the effects of insulin. Resolution of 
this paradox came with the somatomedin hypothesis of growth hormone action 
(Salmon and Daughaday 1957) (Figure 3.3). Accordingly the growth hormone 
effects on carbohydrate and lipid metabolism are direct whereas the growth 
promoting actions are mediated through the somatomedin family of peptides.
Two somatomedin peptides, with molecular weights of approximately 7500 
daltons, have been isolated and because of structural similarities to proinsulin these 
have been termed IGF I (formerly somatomedin C) and IGF II. The overlapping 
biological activities of insulin and the IGF's may be due to the fact that the IGF's 
cross react with the insulin receptor and that insulin cross reacts with the IGF I 
receptor.
3.1.5. Plasma Growth Hormone Estimations in Clinical Practice
The primary role of growth hormone estimation is in the diagnosis of 
acromegaly and in the investigation of the causes of short stature. Growth hormone 
concentrations in plasma describe a distinct circadian rhythm, and this along with 
stress stimulated release, makes single estimations of little value (Parker et al, 
1979). Several dynamic tests are available to overcome this problem.
Active acromegaly is characterised by hypersecretion of growth hormone 
usually as a consequence of a somatotroph adenoma. The diagnosis can best be 
made by showing failure of suppression of plasma growth hormone after an oral
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glucose load. In normal subjects plasma growth hormone falls below 2 mU/1 at 
some point during an oral glucose tolerance test (GTT) (In: Scottish Inter-
Laboratory Services Directory, 1987 ; Stewart et al, 1989). In acromegaly the 
common finding is an elevated fasting growth hormone concentration (>10 mU/1) 
which shows little or no suppression during the GTT.
Investigation into the endocrine causes of short stature involves the 
assessment of growth hormone reserve. The simplest screening procedure is to 
measure growth hormone concentrations before and after strenuous exercise. The 
stress of exercise is normally sufficient to raise growth hormone concentration to 
> 20  mU/1. A response such as this would exclude inadequate growth hormone 
reserve. A blunted or absent response however is not considered diagnostic. The 
most widely used test of growth hormone reserve is the insulin tolerance test. The 
stress of hypoglycaemia is normally sufficient to raise growth hormone 
concentration above 20 mU/1 at some point during the test. Clinical symptoms of 
hypoglycaemia should be observed, and threshold levels of sex steroids 
demonstrated, if results are to be valid. This test is obviously not without risk and 
consequently the alternative clonidine stimulation test has been advocated (Gil-Ad 
et al, 1979). Clonidine (2[2,6-dichlorophenyl)-amino]-2-imidazoline) is a widely 
used anti-hypertensive drug the only side effects of which are drowsiness for a few 
hours and occasionally mild hypotension . Clonidine induction of growth hormone 
secretion is by specific activation of a-adrenergic receptors (Gil-Ad et al, 1979). 
Growth hormone responses are similar to those seen during insulin induced 
hypoglycaemia.
A summary of tests of growth hormone reserve is shown in Table 3.2.
3.1.6. History of the Development of Growth Hormone Assays
Assays of human growth hormone can be divided into four major groups:-
1. Bioassays
2. Radioreceptor assays
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3. Radioimmunoassays
4. Immunometric assays
Bioassays, while remaining fundamental to the measurement of activity of 
purified growth hormone and providing the basis for comparison of reference 
standards, are too insensitive and non-specific for valid measurement of growth 
hormone in blood and tissue fluids. The rat tibial width assay is most commonly 
used and is also the most sensitive (Greenspan et al, 1949). Over a limited range of 
growth hormone doses, the growth of the proximal tibial epiphyseal cartilage in the 
hypophysectomised rat is linearly related to the logarithm of the dose of growth 
hormone administered.
Radioreceptor assays using receptors from a variety of sources have been 
described. Those using binding to a human lymphocyte cell line have proved to be 
quite specific whereas others using receptors derived from rabbit, or rat liver show 
a much wider responsiveness. (Lesniak et al, 1973; Gavin et al, 1982; Lesniak et 
al, 1974). The receptor assays combine to some extent the sensitivity and precision 
of radioimmunoassays with the biological relevance of bioassays. The receptor 
assay of choice, however, requires the availability of tissue culture facilities thus 
limiting its wide-spread use.
The development of the radioimmunoassay for growth hormone (Hunter and 
Greenwood, 1962) and the improvements in radioiodination techniques (Hunter and 
Greenwood, 1964) heralded an explosion in the knowledge of the physiology and 
pathophysiology of growth hormone secretion. The establishment of an 
international reference preparation (IRP 66/217) and the introduction of a U.K. 
external quality assessment scheme overcame the initial problems of between 
laboratory variation. Radioimmunoassay thus became, and has remained, the most 
universally used method for the estimation of growth hormone in plasma for over 
25 years.
Immunometric assays for growth hormone first described in 1968 (Miles and
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Hales), and the subsequently developed two-site immunometric assay, whilst 
having considerable theoretical advantages over the limited reagent 
radioimmunoassay methods, did not initially realise their potential. This was 
primarily due to the use of labelled polyclonal antibodies since the practical 
difficulties of antibody purification and iodination are considerable. The profligate 
use of antibody in excess reagent assays was also a significant disadvantage.
Surprisingly, when monoclonal antibodies specific for growth hormone were 
first produced they were applied to radioimmunoassay methods (Bundesen et al, 
1980). A comparison of the use of monoclonal antibodies in radioimmunoassay and 
immunoradiometric assay, illustrated by a-foetoprotein (Hunter and Budd, 1981), 
clearly demonstrated the benefits of the use of monoclonal antibodies in excess 
reagent methods. Subsequent to these observations several such assays for growth 
hormone have been developed and this technique is gradually replacing the 
radioimmunoassay as the method of choice.
Immunometric assays utilising tracers other than radioiodine have also been 
described. Weeks and Woodhead (1986) developed an immunochemiluminometric 
assay using an acridinium ester labelled monoclonal antibody as tracer; and 
Sukegawa et al (1988) have described an enzyme immunoassay which utilizes an 
antibody peroxidase conjugate. The bound activity of the conjugate is assayed by 
fluorimetry using 3-(p-hydroxyphenyl)propionic acid as substrate.
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3.2. MONOCLONAL ANTIBODY PRODUCTION
Detailed protocols for monoclonal antibody production and assessment are 
described in Chapter 2, sections 2.2.7 to 2.2.13.
3.2.1. Immunisation and Assessment of Response
Six female balb/c mice were immunised with human growth hormone. Each 
mouse received a primary and two secondary doses of immunogen at three week 
intervals. Responsiveness was assessed by comparison of serum antibody titres two 
weeks after the final dose of immunogen. Blood samples were taken onto filter 
paper and antibody dilution curves prepared.
Figure 3.4 shows that all mice responded with M3-M6 having much higher 
titres than M l and M2. Mouse 3, with the greatest antibody titre, was selected for 
hybridisation. Three days prior to the hybridisation experiment a priming dose of 5 
pg of growth hormone in 0.1  ml of saline was administered intravenously.
3.2.2. Hybridisation Experiment
Splenectomy provided a spleen weighing 390 mg, from which 156 x 10^ 
cells were recovered. Myeloma cells (X63. Ag8.653), on the day of the experiment, 
had an estimated viability of 87%. The ratio of spleen cells to myeloma cells for 
fusions was 1:1. Three separate fusions were performed, the products of each 
fusion being dispensed, in 2x HAT medium, into the wells of five 96 x 0.2 ml 
microtitre plates. Peritoneal macrophages, harvested the day prior to the 
hybridisation experiment, were used as feeder cells at a density of 5 x 10 
cells/well.
3.2.3. Assessment of Fusion Experiment and Selection of Hybrids.
Hybrid growth was observed in all wells. Supernatants were removed for 
testing ten days after fusion. A summary of the results of the primary screening
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Figure 3.4 Antibody titres of balb/c mice immunised with 
growth horm one.
assay is shown as a frequency distribution of percentage binding (Figure 3.5). 
98.8% of wells (1423) gave binding in excess of 20%. Further study of 1423 wells 
was considered impractical. It was decided to investigate further the 75 
supernatants which gave binding in excess of 50% and also the three plates which 
contained the largest number of supernatants giving binding in excess of 40%.
A total of 339 supernatants were therefore examined on a secondary 
screening assay, using a displacement dose of 56 mU/1 GH, designed to assess the 
relative avidities of antibodies. The results of this secondary screen are similarly 
presented as a frequency distribution of % inhibition (Figure 3.6). The twelve most 
avid (greatest % inhibition) were selected for cloning.
3.2.4. Cloning and Propagation of Selected Hybrids.
Cloning was performed by a limiting dilution technique. Feeder cells, 
peritoneal macrophages, were provided to aid growth at low cell densities. 
Supernatants were removed for testing 14 days post cloning. The initial test for the 
presence of antibody revealed that only 8 of the 12 cloned continued to secrete 
anti-GH antibody. The results from a typical cloning plate are shown in Table 3.3.
Displacement tests were performed on the supernatants from wells at 
highest dilution still showing the presence of antibody secreting cells. The 
condition and number of cells in these wells was noted. Also observations were 
made as to whether there was significant cell growth in wells, in the same row, at 
higher dilution which did not secrete antibody. Supernatants from two plates were 
found to have lost the displacement characteristics shown originally.
Only two of the remaining six survived 2nd and 3rd cloning stages, retaining 
their binding and displacement characteristics. These were the cell lines coded 
GH3/H10 and GH3/G8. When sufficient numbers of cells had been cultured 
aliquots were frozen. Isotyping of the antibodies from these cells by
immunodiffusion demonstrated IgGl immunoglobulins in both cases.
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Figure 3.5 Production of monoclonal antibodies for growth 
hormone: results of prim ary  screening assay.
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Figure 3.6 Production of monoclonal antibodies for growth 
hormone: results of displacem ent studies.
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Ascitic fluid containing antibody was generated by the intraperitoneal 
injection of 5-10 xlO^ hybridoma cells, in 0.5 ml of RPM1 1640, into pristane 
primed balb/c mice. Five mice were used for each hybridoma cell line. Taps of 
ascitic fluid were taken when there was evidence of abdominal distention, 
approximately 3-4  weeks post injection, and then at about three day intervals as 
necessary. The cell line GH3/G8 gave a very poor yield, only one mouse being 
tapped on more than one occasion. In contrast GH3/H10 cells generated good 
volumes of ascitic fluid on four occasions from four of the five mice injected.
Fluid, from third and fourth taps, generated by the GH3/H10 cell line were 
pooled and the immunoglobulin fraction extracted by the method described in 
Chapter 2 section 2.2.1. The protein content of the purified material was 7.4 
mg/ml. This material was diluted in distilled water and aliquoted at a concentration 
of 20  pg/2 0  pi and subsequently used for radioiodination.
3.3. DEVELOPMENT OF A TWO SITE IMMUNORADIOMETRIC ASSAY
The antibodies used in the development of the two-site immunoradiometric 
assay were the monoclonal antibody GH3/H10, labelled with I, and a SAPU 
sheep anti-GH antibody, coupled to Sepharose CL-4B.
3.3.1. Radioiodination of GH3/H10 Antibody
Radioiodination was by the lactoperoxidase method as described in Chapter
1752, section 2.2.4, using 20 pg of monoclonal antibody and 37 MBq of Iodine. 
Post iodination purification was by gel filtration chromatography on a 60 x 1.6 cm 
column of Sepharose C L -6B. The elution buffer was buffer 3 pumped at a flow 
rate of 10 ml/hr. Fractions (1ml) were collected and intrinsic radioactivity counted 
for 10 seconds.
The iodination profile (Figure 3.7) shows two peaks. The first peak 
comprises the iodinated immunoglobulin followed by a peak of excess radioiodine.
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Figure 3.7 Lactoperoxidase radioiodination of GH3/H10 
monoclonal antibody
125Calculated from the areas under the peaks the percentage of Iodine incorporated 
into the immunoglobulin is 74%. This translates to a specific radioactivity of 1.369 
MBq/pg immunoglobulin.
3.3.2. Preparation of Solid-Phase Sheep Anti-GH
A partially purified immunoglobulin fraction from sheep anti-GH antiserum 
was prepared by n-octanoic acid precipitation and coupled to Sepharose CL-4B by 
the methods described in Chapter 2, section 2.2.1 and 2.2.3 respectively. The final 
product was stored at 10 mg/ml Sepharose CL-4B in buffer 4 at 4 °C.
3.3.3 Compatibility of GH3/H10 with the Sheep Anti-GH
For optimal performance a two-site IRMA requires a pair of antibodies 
which recognise distinctly different antigenic binding sites , or epitopes. In this 
context compatibility of two antibodies can be demonstrated by the production of a 
dose response curve.
Growth hormone standards were prepared covering the range 0-560 mU/1. 
Duplicate aliquots of growth hormone standards (0.1 ml) were incubated static at 
ambient temperature with radiolabelled GH3/H10 monoclonal antibody (0.1 ml = 2 
ng) for 90 minutes. Sepharose CL-4B coupled sheep anti-GH (0.2 ml = 2mg) was 
then added and incubated for a further 90 minutes with shaking. The Sepharose 
particles were then subjected to three centrifuge/wash cycles with 2ml of saline. 
Bound radioactivity was counted for 60 seconds.
The resultant dose response curve is shown as Figure 3.8. The percentage 
radioactivity bound rises from 0.45% at zero dose to 31.6% at 140 mU/1 GH, a 
change of 70 fold. Binding is maintained at 560 mU/1 GH, indicating sufficient 
binding capacity of the solid-phase antibody to avoid misclassification of growth 
hormone measurement in normal clinical practice due to the high dose-hook effect.
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Figure 3.8 Initial dose response curve for growth hormone 
IRMA.
3.3.4. Preliminary Optimisation of Assay Conditions
In the optimisation of a two-site IRMA several major factors require 
consideration i.e. precision and bias, the extent of the working range, speed and 
convenience. The final product is a balance of these various factors.
Studies were performed varying buffer pH and protein content, radiolabelled 
antibody mass and specific activity, solid-phase antibody mass, incubation times 
and solid-phase wash conditions. The effects of varying conditions were assessed 
arbitrarily on the basis of improvements in signal/noise ratio ( the product of 
binding at 140 mU/1 GH and 0 mU/1 GH ) and more specifically the precision 
profile and the concentration at which a hook effect occurred. In the interests of 
brevity data from the many individual experiments is excluded. The overall 
optimised conditions are as follows:-
a) Buffer- 0.1M EPPS buffer pH 8.0 containing 0.5% non-immune 
sheep serum and 0.2% Tween-20.
b) 125i Anti-GH -  specific radioactivity 555-740 Bq/pg, adding 
100 ,000  cpm/tube.
c) Solid-phase anti-GH -  0.5 mg/tube in 0.2 ml assay buffer
d) Incubation periods -  i) 120 minutes -  sample and 125l anti-GH
ii) 60 minutes -  post addition of solid-phase 
anti-GH
e) Wash conditions -  4 x 2 ml of saline.
3.3.5. Standardisation
The solvent used in the preparation of standards can have a significant effect 
on assay bias. Various potential matrices were evaluated by estimating the 
recovery of exogenous growth hormone standard added to serum samples.
Three serum samples with growth hormone concentration of 2.1, 7.3, and 
16.0 mU/1, as measured by RLA, were each supplemented with 8.75 and 17.0 mU/1
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of growth hormone standard. The growth hormone concentrations in both 
supplemented and basal samples were measured in five assays each of which had a 
different standard matrix. Figure 3.9 shows the five standard curves from which 
serum concentrations were interpolated.
The recoveries of exogenous growth hormone from each of the samples is 
shown in Table 3.4. The values in italics are the concentrations of the basal 
samples derived from each of the standard curves. The phosphate buffer based 
standards give basal values closest to those of the RIA, however the recovery of 
only 62% hormone was unacceptable. The EPPS buffer standards appeared to give 
the best balance between comparability with RIA and recovery.
An ideal standard matrix would be growth hormone free human serum. Two 
approaches to the production of growth hormone free serum were considered, either 
immunoextraction, or the physiological suppression of growth hormone in normal 
volunteers by the administration of an oral glucose load.
Immunoextraction was attempted using sheep anti-GH coupled to 
Sepharose CL-4B. A pilot experiment was conducted to determine the mass of 
solid phase antibody required to remove all the growth hormone from a human 
serum sample from a normal volunteer. To 6 x 1 ml of serum 50 pi of 125j growth 
hormone was added (10,000 cpm). An increasing mass of solid phase anti-GH was 
added to five of the tubes covering the range 0.5 -  4.0 mg/tube. The sixth tube was 
used as a reference and buffer was added in place of the solid phase anti-GH. All 
tubes were mixed, end over end, for 6 hours prior to centrifugation and removal of 
0.1 ml aliquots for counting. The tubes were mixed for a further 18 hours and a 
further aliquot removed for counting. Figure 3.10 shows the percentage of 125j 
growth hormone remaining in the sample, relative to the mass of solid phase anti- 
GH added, for both incubation periods. Since there was no apparent improvement 
beyond 1 mg of solid phase/ml of serum this ratio was used on a larger scale 
without the addition of 1251 growth hormone.
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F igure 3.9 Effect of standard  m atrix on dose response curve 
for growth hormone IRMA.
FCS = Foetal calf scrum : BS = Bovine scrum : HS = Horse serum : 
P04 = Phosphate b u ffe r: EPPS = EPPS buffer.
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Figure 3.10 Percentage ll25_grow th horm one im m unoextracted 
from human serum.
Physiological pools were obtained from 4 volunteers who, after an overnight 
fast, were given 75g of glucose orally. Blood was withdrawn 30 -  45 minutes post 
ingestion of the glucose. The growth hormone concentration on all samples was 
<1.0 mU/1 as measured by RIA. The effectiveness of suppression in each of these 
pools was compared by their utilisation as the standard matrix in IRMA dose 
response curves. Figure 3.11 shows that at growth hormone concentration above 6 
mU/1 the dose response curves are superimposable. The divergence at low 
concentration suggests that pools 3 and 4 probably contained higher concentrations 
of growth hormone. Pool 2 was selected for use in recovery experiments.
A recovery experiment was conducted using immunoextracted and 
physiologically suppressed growth hormone free human serum as the standard 
matrices. Three samples were each supplemented with 4.38, 8.75 and 17.5 mU/1 of 
growth hormone. Each of the supplemented samples was assayed together with the 
appropriate basal samples. The calculated recoveries and the basal concentrations 
are shown in Table 3.5. Recoveries using the physiologically suppressed serum as 
standard matrix ranged from 83% to 113%, the average of the nine pools being 
99.7%. The immunoextracted serum as standard matrix however over estimated the 
exogenous growth hormone added by on average 36%.
Physiologically suppressed serum was adopted as the optimal standard
matrix.
3.4. ANALYTICAL VALIDATION
Prior to routine use the analytical validity of results produced by the IRMA 
was assessed by comparison with an established RIA, and by reference to the 
means of serum pools previously distributed by the U.K. External Quality 
Assessment Scheme (EQAS).
Stability and performance over a protracted period was assessed by routine 
computation of precision profiles, reference to internal quality control pools and
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Figure 3.11 Dose response curve for growth horm one IRMA
using glucose suppressed serum , from  four normal 
volunteers, as s tandard  m atrix.
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participation in EQAS.
The cross reactivity of structurally related hormones was also examined.
3.4.1. Comparison of IRMA with RIA
Three hundred samples were analysed in 3 assays including 10 samples 
distributed by EQAS. The correlation of results was good (correlation coefficient 
0.9988), however the gradient of 0.863 without a significant intercept showed that 
the results by IRMA were 14% lower than those obtained by RIA. This was 
confirmed by comparison of the results on EQAS pools (Table 3.6). Relative to the 
all laboratory trimmed mean (ALTM) the RIA on average under estimates by 3.6% 
as compared to the IRMA's which under estimates by 18.4%.
This discrepancy was traced to a difference in the potency of the primary 
standards used in these assays. The IRMA was calibrated with IRP 66/217 
standards while the RIA was calibrated using the U.K. 7 working standard 
commonly used by EQAS participants.
When U.K. 7 was used as the primary standard in both assays no systematic 
difference in results of EQAS pools was seen (Table 3.6). The potency difference 
between these standards was drawn to the attention of EQAS and at the time of 
writing is under investigation.
3.4.2. Internal Quality Control
a) Intra-assay precision.
Intra-assay precision was monitored by the computation of precision 
profiles using the WHO data reduction program. All duplicate estimations within 
an assay batch are used, the relative error (CV) being plotted against dose. A 
typical precision profile is shown in Figure 3.12. A coefficient of variation of less 
than 10% over the range 1-250 mU/1 is achieved, and at the clinically important 
concentration of 20 mU/1 a CV of <2% is observed. Within assay sensitivity as
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Figure 3.12 W ithin assay precision profile of optimised growth 
horm one IRMA.
defined by the dose at 22% CV (McConway et al, 1989) is 0.5 mU/1.
b) Inter assay precision.
Four pools of GH supplemented human serum are assayed in all batches. 
Figure 3.13 summarises the data derived from these pools on a monthly basis. A 
period of 11 months is shown. Mean pool concentrations over this extended period 
are 2.9, 10.9, 20.1 and 39.9 mU/1 with respective mean CV's of 14.4, 8.7, 6.9 and 
6.3%.
3.4.3. External Quality Assessment
External quality assessment data over the same extended period is shown in 
Figure 3.14. Percentage bias from the ALTM and the percentage variability of that 
bias are cumulative statistics calculated for each distribution based on the previous 
six months data. The introduction of the U.K. 8 working standard caused a shift in 
bias which is reflected initially as increasing variability of the bias.
Three months following the introduction of U.K. 8 standard a shift in bias of -30% 
on internal QC pools was noted. This was confirmed by retrospective analysis of 
EQAS pools. The U.K. 8 standard potency was therefore reassigned internally and 
the EQAS organisers informed. Other users of U.K. 8 have reported a similar 
problem.
3.4.4. Cross Reactivity Studies
There is considerable size and sequence homology in the primary structures 
of growth hormone , placental lactogen and prolactin most probably due to gene 
duplication (Wallis, 1985). The potential for interference from physiological and 
pathological concentrations of placental lactogen and prolactin in the growth 
hormone IRMA was therefore assessed.
a) Prolactin
In the IRMA growth hormone standards were substituted with prolactin
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Figure 3.13 Inter-assay precision for optimised growth hormone IRMA.
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standards (0 -1980 jjig/1). The highly purified prolactin was a gift from Dr. S.S. 
Lynch and is known to contain 0.015% growth hormone. Figure 3.15 shows the 
resultant dose response curve in comparison with the growth hormone dose 
response curve (0-119 pg/1). The percentage binding equivalent to 0.65 p,g/l of 
growth hormone is obtained by 750 pg/1 of prolactin. This translates to an observed 
0.087% cross reaction with prolactin (0.072% after subtraction of known growth 
hormone contamination).
Since growth hormone contamination of prolactin standards can be a major 
problem and cross reaction in an IRMA is not necessarily additive, recovery 
experiments on samples from hyperprolactinaemic patients were conducted. Five 
samples with prolactin concentrations ranging from 1000-34000 mU/1 were each 
supplemented with 14.8 mU/1 of growth hormone. Growth hormone concentrations 
in basal and supplemented samples were measured and recovery of exogenous 
growth hormone calculated (Table 3.7). Quantitative recovery was obtained for all 
but the specimen with the highest prolactin concentration.
b) Placental lactogen
The same experiments as described above were performed using placental 
lactogen (lU /g UCB Bioproducts, Belgium) in place of prolactin. Standards were 
prepared covering the range 0-50000 pg/1. Comparison of standard curves is shown 
in Figure 3.15 from which cross reactivity is calculated to be 4.7%. Recovery 
experiments were conducted in samples from patients in the third trimester of 
pregnancy who were assumed to have elevated placental lactogen concentrations. 
Recovery data is shown in Table 3.8 and reveals a complete inability to measure 
added growth hormone.
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3.5. CLINICAL VALIDATION
Observations on basal blood samples are of little clinical value since growth 
hormone concentrations are affected by stress and show a circadian rhythm. It is 
common clinical practice to use dynamic tests of growth hormone suppression or 
stimulation as aids to diagnosis. Therefore, in assessing the clinical validity of the 
IRMA dynamic tests were examined.
3.5.1. Suppression Tests
The suppression test of choice in the diagnosis of acromegaly is the GTT, 
during which blood samples are withdrawn before the administration of 75 g of 
glucose and then at 30 minute intervals post glucose for two hours. Figure 3.16 
shows the results of growth hormone estimations from the GTTs of three patient 
groups.
Group one consisted of 13 subjects,9 female, 4 male, with a mean age of 
45.6 years (range 19 -  62), with some clinical features of acromegaly who after 
investigation were considered not to have acromegaly. The mean basal 
concentration was 2.75 mU/1 falling to a nadir of 0.56 mU/1 at 60 minutes post 
glucose.
The second group, of 8 subjects, presented with clinical features of 
acromegaly and after investigation had the diagnosis confirmed and were 
subsequently treated by pituitary surgery. There were 4 male and 4 female subjects 
with a mean age of 48.8 years. Individual data is shown for each subject. Basal 
concentrations ranged from 11 -  185 mU/1 and all subjects showed a lack of 
suppression of growth hormone concentration throughout the GTT.
Group three consisted of 10 subjects, 6 male and 4 female, with a mean age 
of 48.8 years (range 41 -  63), previously treated for acromegaly by pituitary 
surgery and/or irradiation in whom there was still clinical evidence of active 
disease. The mean basal growth hormone concentration was 9.3 mU/1 which failed
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Figure 3.16 Clinical validation of optimised growth hormone 
IRMA: glucose tolerance tests.
O----- O = Group 1 ± SEM : ----------= Group 2 (individual patients)
A----- A = Group 3 ± SEM .
to suppress at any time during the GTT.
3.5.2. Stimulation Tests.
In patients suspected of growth hormone deficiency stimulation tests are 
used to assess growth hormone reserve. The non-invasive exercise test is 
frequently used as a primary screen, a response to >20 mU/1 excluding growth 
hormone deficiency. An inadequate response however requires further 
investigation most commonly in the form of an insulin tolerance test or less 
frequently the clonidine stimulation test.
i) Exercise test.
Figure 3.17 shows growth hormone concentrations from two groups of 
subjects before and 30 minutes following vigorous exercise. Group one consisted 
of 10 subjects, 6 male and 4 female with a mean age of 14.3 (range 11-18 ),with 
clinical features of growth hormone deficiency and in whom the diagnosis was 
subsequently confirmed. All subjects in this group showed a blunted or absent 
response to the stress of exercise. The 10 subjects in group two, 5 male and 5 
female, mean age 13.4 years (range 12 -  14) while presenting with some clinical 
features of growth hormone deficiency showed a rise in growth hormone 
concentration to levels >20 mU/1 and were therefore not further investigated.
ii) Insulin tolerance test
The data from three groups of subjects subjected to an insulin tolerance test 
are shown in Figure 3.18 Samples were withdrawn prior to the intravenous 
administration of 0.15 U/Kg insulin and then at 30, 45, 60, 90 and 120 minutes post 
insulin.
Group one consisted of 18 subjects, 13 female and 5 male, with a mean age 
of 33.6 (range 10 -  75) who were being investigated either for growth hormone 
deficiency or hypopituitarism but who were considered to have adequate growth 
hormone reserve. The mean basal concentration was 2.9 mU/1 rising to a peak of
GII (mU/1)
50 -l
40 -
30 -
20  -
10 -
1209 06 00 3 0 4 5
Minutes post insulin
Figure 3.18 Clinical validation of optimised growth horm one 
IRM Aiinsulin tolerance tests.
O O = Group 1: A A = Group 2 : 0  0 = Group 3.
± SEM
35 mU/1 60 minutes post insulin.
The second group consisted of 10 subjects, 4 female and 6 male, with a 
mean age of 39.9 years (range 16 -  75) who were investigated for hypopituitarism 
and in whom the diagnosis was subsequently confirmed. The mean basal growth 
hormone concentration in this group was 0.4 mU/1 rising to 2.4 mU/1 at 45 minutes 
post insulin. Adequate hypoglycaemia was demonstrated (glucose <2.2 mmol/1) at 
some point during the test.
Group three were subjects in whom a diagnosis of isolated growth hormone 
deficiency was established. This group consisted of 11 subjects, 5 male and 6
female, with a mean age of 12.8 years (range 6 -  19). The mean basal
concentration was 2.1 mU/1 rising to 4.9 mU/1 at 45 minutes post insulin. Adequate 
hypoglycaemia was demonstrated at some point during each test.
iii) Clonidine stimulation test
The data from two groups of subjects subjected to a clonidine stimulation 
test are shown in Figure 3.19 Samples were withdrawn prior to the oral
administration of 4 [xg/Kg clonidine and then at 30 minute intervals for 120
minutes.
Group one is comparable to group one as described for the ITT. This group 
consisted of 13 subjects, 8 male and 5 female, with a mean age of 10.4 years (range 
4 -  16). The mean basal concentration was 3.9 mU/1 rising to a peak of 37 mU/1 60 
minutes post clonidine.
The second group of ten subjects, (7 male and 3 female), with a mean age of
13.1 years (range 7 -  18) was a group of growth hormone deficient children. The 
mean basal concentration was 2.5 mU/1 rising to a peak of 5.6 mU/1 90 minutes post 
clonidine.
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Figure 3.19 Clinical validation of optimised growth hormone 
IRMA: clonidine stim ulation test.
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3.6 CONCLUSIONS
A monoclonal antibody to human growth hormone has been produced and 
successfully utilised in a two-site immunoradiometric assay. The assay has a wide 
working range (0.4-200 mU/1), is both precise and accurate, and can be completed 
within a working day. In a clinical context the IRMA gives the same discrimination 
as the RIA it supersedes.
The cross reaction studies with prolactin and placental lactogen illustrate a 
significant difference between RIA and IRMA. In RIA's cross reactive material will 
always give an additive effect while in IRMA's , since the specificity and relative 
affinity for the antigen of two antibodies has to be taken into account, under- 
recovery is more likely. The only apparent disadvantage of the IRMA is the 
inability to measure growth hormone during pregnancy. There is also evidence to 
suggest that growth hormone concentration may be under-estimated in samples that 
have prolactin concentrations in excess of 30000 mU/1. This interference from 
prolactin should not give rise to clinical misclassification.
Human growth hormone is a particularly good immunogen.This is due to the 
lack of homology in the stucture of growth hormone between species (Wallis, 
1985).The response of the immunised mice to growth hormone and favourable 
fusion conditions led to the generation of secreting hybridomas in 98.8% of the 
seeded wells. This is not a particularly desirable situation since the number of wells 
containing multiple hybridoma colonies will be large, leading to subsequent 
problems in cloning out a hybrid cell line with the desired properties. The pressure 
of time when performing screening assays is also magnified when such large 
numbers have to be processed and consequently detailed investigation of all 
potentially useful cell lines is not practicable.
Attempts to immunoextract growth hormone from serum proved to be 
disappointing. The inability to remove more than 50% of exogenous I^ ^ G H  from 
serum (Figure 3.10) may be explained by the existence of recently described
90
growth hormone binding proteins (Bauman, 1988).
This growth hormone assay has been in routine use in the Clinical 
Biochemistry Department at Glasgow Royal Infimary for over a year and has 
proved to be a significant improvement on the RIA which it replaced.
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CHAPTER 4
PARATHYROID HORMONE : THE PRODUCTION OF A MONOCLONAL 
ANTIBODY AND ITS APPLICATION TO AN IMMUNORADIOMETRIC
ASSAY
4.1 INTRODUCTION
4.1.1. Structure of Parathyroid Hormone
Parathyroid hormone is a single chain polypeptide consisting of 84 amino 
acid residues (Figure 4.1) having a molecular weight of 9425 daltons. It has no 
intra-chain disulphide bridges.
Parathyroid hormone has not been crystallised and therefore its tertiary 
structure is not known. Indications as to its three dimensional structure have been 
derived from hydrodynamic studies (Cohn et al, 1974), dark-field electron 
microscopy (Fiskin et al, 1977), and optical measurements (Cohn & MacGregor, 
1981: Brewer et al, 1975: Edelhoch & Lippoldt, 1969). The results of these studies 
together with predictive formulas (Chou & Fasman, 1974a : Chou & Fasman, 
1974b: Fasman et al, 1976 : Chou & Fasman, 1977) have produced a physical 
model consisting of two domains connected by a short stalk, the biologically active 
amino-terminal region occupying one domain and the carboxy-terminal region the 
other. Residues 30-40 are thought to constitute the connecting stalk because of the 
ease with which enzymes cleave parathyroid hormone in this portion of the 
hormone (Fiskin et al, 1977).
4.1.2. Biosynthesis of Parathyroid Hormone
The biosynthesis of parathyroid hormone takes place in the chief cells of the 
parathyroid glands.
In humans there is a single parathyroid hormone gene, containing two 
introns (non-coding regions), located on the short arm of chromosome 11 (Naylor 
et al, 1983: Kronenburg et al, 1986). The primary messenger RNA translation 
product, pre-proparathyroid hormone, undergoes a two step proteolytic cleavage to 
yield first proparathyroid hormone and then the native hormone. Proparathyroid 
hormone has a six amino acid extension to the N-terminus of the native molecule
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Figure 4.1 T he Prim ary Structure o f P reproparath yroid  H orm one
and pre-proparathyroid hormone has a further extension of 25 amino acids (Figure 
4.1). The respective molecular weights of these precursors are 10200 and 13000 
daltons (Cohn & MacGregor,1981). The pre-proparathyroid extension is thought to 
be a signal peptide facilitating the binding of the ribosome to the endoplasmic 
reticulum and the transport of proparathyroid hormone into the cisternal space. The 
proparathyroid hormone extension probably facilitates transport within the cisternal 
space from the rough endoplasmic reticulum to the Golgi apparatus at which point it 
is removed (Cohn & MacGregor, 1981). Some parathyroid hormone is stored in 
secretory granules until released into the circulation. However, mature secretory 
granules are scarce in the parathyroid gland, immature vesicles being more 
abundant. This has led to the suggestion that a proportion of the parathyroid 
hormone may be transported directly to the periphery of the cell without being 
packaged into granules (MacGregor et al, 1975).
Pulse chase experiments have shown that pre-proparathyroid hormone has a 
half-life of <1 minute and the half-time for the conversion of proparathyroid 
hormone to parathyroid hormone is approximately 10  minutes.
Figure 4.2 shows a diagrammatic representation of parathyroid hormone 
biosynthesis.
4.1.3. Factors Controlling Parathyroid Hormone Concentrations.
The principal factor controlling parathyroid hormone secretion is the 
concentration of ionised calcium in the blood (Patt & Luckardt, 1942: Sherwood et 
al 1968), there being an inverse relationship. This relationship is non linear; as the 
ionised calcium concentration falls below the physiological set point of 1.3 mmol/1 
so the rate of secretion of parathyroid hormone rises exponentially (Mayer & 
Hurst, 1978).
The assumption that the synthesis of parathyroid hormone increases when 
calcium ion concentration is low and secretion is high appears not to be the case. It
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Figure 4.2 Synthesis and Secretion o f  P arathyroid  H orm one in the Parathyroid  Cell
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has been found that the rate of synthesis and turnover of proparathyroid hormone is 
the same regardless of calcium status. The experiments of Morrissey and Cohn 
(1979) and Chu et al (1973) indicate that calcium affects hormone production 
through control of intracellular degradation, not synthesis.
Several other factors have been reported to affect parathyroid hormone 
synthesis and or secretion, notably magnesium (Buckle at al 1968: Targovnik et al 
1971), cyclic adenosine monophosphate (cAMP)(Abe & Sherwood, 1972) and 
catecholamines (Williams et al, 1973: Kukrega et al 1976). Calcitonin at
pathological concentrations causes release of parathyroid hormone (Fischer et al, 
1971: Sherwood & Abe, 1972) but there is currently no clear evidence of a
physiological control mechanism. The role of vitamin D metabolites remains 
unclear.
4.1.4. Circulating Fragments of Parathyroid Hormone.
In 1968, Berson and Yalow reported that parathyroid hormone in peripheral 
human plasma was heterogeneous. This heterogeneity is now universally 
acknowledged.
The intact, biologically active hormone has a circulating half-life of 
approximately 10  minutes and represents only about 1 0% of the immunoreactivity 
detected in peripheral plasma. Amino-terminal fragments of the hormone, also 
with a short half-life and possibly biologically active, may represent 5-10% of the 
circulating immunoreactivity. Carboxy-terminal fragments of the peptide 
constitute approximately 80% of the immunoreactivity in peripheral human plasma. 
Carboxy-terminal fragments are biologically inactive and have a long circulating 
half-life. Inactive mid-region fragments may also be present in the circulation 
(Roos et al, 1981: Marx et al, 1981).
The source of these fragments and their biological significance remains a 
controversial issue.
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4.1.5. Physiological Effects of Parathyroid Hormone.
The parathyroid glands, through the integrated actions of parathyroid 
hormone, are primarily responsible for the regulation of mineral homeostasis. This 
control results from the direct effects of parathyroid hormone on calcium and 
phosphorus metabolism in the kidney and in bone.
a) Effects on kidney.
The principal actions of parathyroid hormone on kidney are two-fold. 
Firstly to stimulate the renal excretion of phosphate and to enhance the renal tubular 
reabsorption of calcium. These effects are thought to be mediated by adenyl 
cyclase stimulating the formation of cAMP from ATP. Secondly to stimulate the l a  
hydroxylation of 25-hydroyxcholecalciferol thus indirectly controlling intestinal 
absorption of calcium and phosphorous.
b) Effects on bone.
The actions of parathyroid hormone on bone are complex and not yet fully 
understood. The response of bone to parathyroid hormone is biphasic. The 
immediate action is largely that of bone mineral mobilisation elevating blood levels 
of calcium and phosphorous. These effects may be seen within minutes following 
hormone administration. A second or slower action of parathyroid hormone is its 
effect upon bone cell activity. Parathyroid hormone is believed to increase the size 
and number of osteoclasts (bone-resorbing cells), thus upsetting the balance 
between osteoblasts (bone-forming cells) and osteoclasts leading to an increased 
rate of bone remodelling. The net effect is usually a net negative skeletal balance 
of calcium and phosphorous. Also associated with prolonged bone resorption is an 
increased release of lysosomal enzymes so that there is a mobilisation of bone 
matrix which results in increased blood levels of hydroxyproline.
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4.1.6. Plasma Parathyroid Hormone Estimations in Clinical Practice.
The measurement of the concentration of plasma immunoreactive 
parathyroid hormone concentration is of value in the investigation of patients with 
hypocalcaemia or hypercalcaemia. The relative clinical value of an assay for 
parathyroid hormone will depend upon its specificity and the circulating forms of 
immunoreactive parathyroid hormone present (see section 4.1.7.)
Hypocalcaemia may result from a primary defect in calcium metabolism 
which cannot be corrected by compensatory increases in parathyroid hormone 
secretion (osteomalacia, chronic renal failure). Alternatively, the primary defect 
may be impaired synthesis and or secretion of parathyroid hormone 
(hypoparathyroidism) or target organ resistance to parathyroid hormone due to 
defective hormone-receptor interaction (pseudohypoparathyroidism).
Hypercalcaemia may also be the result of either parathyroid hormone 
dependent or parathyroid hormone independent causes. In the former, 
hypercalcaemia is accompanied by elevated plasma parathyroid hormone 
concentration (hyperparathyroidism) whereas in the latter the plasma parathyroid 
hormone concentration is suppressed (malignant hypercalcaemia, hypervitaminosis 
D, etc.).
It is increasingly being recognised that the interpretation of a plasma 
parathyroid hormone concentration result may be complemented by knowledge of 
plasma and or urinary cyclic AMP status. This is especially important in the 
investigation of pseudohypoparathyroidism and in situations where there are high 
concentrations of immunoreactive but biologically inactive fragments of 
parathyroid hormone.
For a detailed review of this topic the reader is refered to "Calcium 
Homeostasis :Hypercalcemia and Hypocalcemia"(Mundy,1989).
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4.1.7 History of the Development of Parathyroid Hormone Assays.
Assays for the measurement of PTH in plasma can be divided into three 
broad groups:-
1) Bioassays
2) Radioimmunoassays
3) Immunometric assays
Many of the original bioassays of parathyroid hormone are too insensitive 
for measurements of plasma concentrations. However, the cytochemical bioassay 
based on determination of glucose-6-phosphate dehydrogenase (G6PD) activity in 
the distal convoluted tubules of the guinea pig kidney is reported to be able to 
distinguish hormonal activity in plasma from normal, hypoparathyroid and 
hyperparathyroid subjects. (Goltzman et al, 1980; Fenton et al, 1978). This is a 
particularly sensitive assay however, it is also cumbersome and time consuming and 
therefore not generally available. An alternative bioassay is that based on the use of 
guanyl nucleotide-amplified renal adenylate cyclase which has been reported for 
human renal cortical plasma membranes (Nissenson et al, 1981; Niepel et al, 1983). 
The principle of the procedure is the biological activation by human parathyroid 
hormone of adenylate cyclase in membrane-enriched homogenised renal cortical 
tissue; the adenylate is quantitated by radioimmunoassay of the generated cAMP. 
This assay is not as sensitive as the cytochemical bioassay but may be more 
practical.
Radioimmunoassay of parathyroid hormone was first described by Berson et 
al 1963. A plethora of assays have subsequently been described. The narrow 
specificity of antisera has been a hinderance to the development of clinically 
meaningful assays because of the existence of significant concentrations of 
circulating parathyroid hormone fragments. The radioimmunoassays described to - 
date can be divided in four broad groups, those using:-
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1) N-terminal specific antisera
(Silverman & Yalow,1973; Amaud et al,1974)
2) C-terminal specific antisera
(Reiss & Canterbury, 1968; Hawker et al, 1984)
3) Mid-molecule specific antisera
(Marx et al,1981; Roos et al,1981)
4) Immunoextraction followed by RIA with one of the above
(Lindall et al,1983)
N-terminal specific assays, despite theoretical advantages, have proved to 
be disappointing in their discrimination between normal and primary 
hyperparathyroid subjects, primarily because of poor sensitivity. However N - 
terminal assays are useful for evaluating the parathyroid status of patients with 
chronic or acute renal failure (Hawker et al, 1983) and for evaluating venous 
catheterisation samples in diagnosing patients with hypercalcaemia of malignancy 
(Hawker et al, 1983; Martin et al,1980).
C-terminal and mid-molecule parathyroid hormone assays have provided a 
clearer clinical discrimination between normal and abnormal parathyroid function, 
the C-terminal assays being slightly better than the mid-molecule assay. (Amaud 
et al, 1974; Martin et al ,1980; Hawker et al, 1983). These assays are of limited 
value in patients with hypercalcaemia of malignancy and impaired renal function 
because of the accumulation of C-terminal fragments.
The method of Lindall et al (1983), a two step procedure, involves the 
extraction and concentration of serum PTH moieties using solid-phase bound anti- 
N-terminal antibody. The immunoextract is then assayed by RIA using a mid­
molecule antibody. This method was the first to measure intact 1-84 parathyroid 
hormone and was reported to give clear distinction between normal subjects and 
subjects with proven primary hyperparathyroidism.
The first immunometric assay for parathyroid hormone was that of Addison
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et al (1971). This assay and that of Papapoulous et al (1980) are of the type 
descibed by Miles and Hales (1968^) utilising a single radiolabelled antibody and 
offer no advantage in terms of specificity over the region specific 
radioimmunoassays. Blind et al (1987) described a two-site assay using polyclonal 
antibodies, one a partially purified goat anti-N-terminal coupled to cellulose 
particles,the other a rabbit anti-C-terminal antibody which was indirectly 
radiolabelled following sandwich formation by incubation with a C-terminal 
radiolabelled fragment (Tyr52-hPTH53-84). While offering some improvement in 
specificity for the intact 1-84 molecule the assay design limits sensitivity.
Nussbaum et al (1987) utilised two goat immunoaffinity purified polyclonal 
antibodies. The N-terminally directed antibody being radiolabelled and the C - 
terminal antibody immobilised by adsorption onto polystyrene beads. This assay 
forms the basis of the commercially available Allegro™ kit, and is both sensitive 
and specific for intact 1-84 parathyroid hormone.
The two-site principle has also been applied by Brown et al (1987) in a 
chemiluminometric assay. The assay depends upon the formation of an immune 
complex of acridinium ester-labelled sheep polyclonal anti N-terminal parathyroid 
hormone, intact parathyroid hormone, and particulate solid phase monoclonal 
mouse anti mid-molecule parathyroid hormone. This assay is commercially 
available in the form of the Ciba-Coming M agic-Lite™  kit.
Another two-site assay measuring intact parathyroid hormone is that 
supplied by Incstar. This assay is identical in design to the Allegro™  system. 
Clinical utility has been found to be improved in comparison to radioimmunoassays 
(Ratcliffe et al, 1989).
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4.2 MONOCLONAL ANTIBODY PRODUCTION
The strategy adopted in this project reflects the primary aim of producing a 
two-site immunoradiometric assay for the measurement of intact 1-84 parathyroid 
hormone. Pre-determination of antibody specificity was assured by utilising 
synthetic parathyroid hormone fragments as immunogens. This approach attempts 
to maximise the chances of producing the required complimentary pair of 
monoclonal antibodies.
4.2.1 Immunisations and Assessment of Response
Synthetic peptides from both the N and C terminal fragments of parathyroid 
hormone were used as immunogens. The 1-34 and 53-84 fragments were used 
alone and also conjugated to bovine albumin. Conjugation was by the 
glutaraldehyde method described by Orth, 1979. Commercially prepared conjugates 
of the N-terminal undecapeptide and the C-terminal nanopeptide were also tried. 
These peptides were conjugated to KLH (keyhole limpet haemocyanin) via a bis- 
diazotised tolidine linkage.
Each of these preparations was used to immunise three strains of mouse and 
two strains of rat. Primary subcutaneous immunisation was followed by two booster 
doses at three week intervals. Test bleeds were taken three weeks following the 
final dose. Table 4.1 summarises the results of the screening assay in which serial 
dilutions of animal sera were incubated for 18 hours with either 1^25 labelled 
PTH1-34 or PTH53-84. The bound fraction was separated by incubation with 
either Sepharose coupled sheep anti-rat polyclonal antibody or sheep anti-mouse 
polyclonal antibody.
The albumin conjugates were also used to immunise sheep. A response was 
elicited but these antibodies were found to be of low avidity.
The response of DA rats to the 1-34PTH fragment was particularly good, all 
animals showing a high titre response. These DA rats were used in a series of
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hybridisation experiments.
4.2.2 Hybridisation Experiments
Four days prior to each of the hybridisation experiments the selected rat was 
given an intra-jugular injection via the pectoral muscle of 50pg 1-34PTH. 
Splenectomies on average provided spleens weighing lg.
Two groups of hybridisation experiments were conducted, using either the 
rat myeloma cell line YO ( a gift from Dr. C. Milstein ) as fusion partner or the 
mouse myeloma cell line X63.Ag8.653. Myeloma cells were maintained in 
logarithmic growth for at least one week prior to the hybridisation experiment and 
on the day of the experiment had an estimated viability of >90%. The ratio of 
spleen cells to myeloma cells for fusion was 1:1. Three separate fusions were 
performed during each experiment, the products of each fusion being dispensed, in 
2x HAT medium, into the wells of five 96 x 0.2ml microtitre plates. Mouse 
peritoneal macrophages, harvested the day prior to the hybridisation experiments, 
were used as feeder cells at a density of 5x10^ cells/well.
4.2.3 Assessment of Hybridisation Experiments
In the two hybridisation experiments using the YO myeloma cell line hybrid 
growth was poor and no stable colonies were evident.
The three cross-species hybridisations, however, repeatedly generated 
growing hybrids in over 50% of wells. Supernatants were removed for testing ten 
days after fusions. The screening assay involved the incubation of 50pl of 
supernatants with 1^25 1-34PTH for 18 hours followed by separation of the bound 
fraction with a Sepharose coupled polyclonal sheep anti-rat antibody. In total 39 
secreting hybrids were found, five of which survived cloning. The antibodies from 
these cell lines were isotyped by immunodiffusion (Table 4.2).
Ascitic fluid containing antibody was generated by intraperitoneal injection
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Table 4.2 ISOTYPES OF ANTI-PTH 1-34 MONOCLONAL ANTIBODIES
Antibody Code Iso ty p e
1D1 IgG2b
3B3 IgG2b
4G3 IgG2a
6E3 IgG2a
9E3 IgM
of 5-10 xlO^ hybridoma cells, in 0.5ml of RPMI 1640, into pristane primed 
athymic (nude) mice. Taps of ascitic fluid were taken when there was evidence of 
abdominal distention. All five cell lines gave good yields.
Figure 4.3 shows the antibody titres of sequential taps from a mouse primed 
with the 6E3 cell line. Antibody titre increases as a function of tap number up to tap 
4 and then declines. Taps 3 and 4 for each cell line were pooled and the 
immunoglobulin fraction extracted by n-octanoic acid precipitation (Chapter 2, 
section 2 .2 .1).
4.2.4 Assessment of Monoclonal Antibodies
The selection of the most appropriate of these monoclonal antibodies for use 
in an intact 1-84PTH IRMA was based primarily on their relative affinities for 1- 
84 PTH. Some attempt was also made to localise the binding sites of these 
antibodies.
Dilution/displacement experiments were conducted with equimolar 
concentrations of 1-10PTH, 1-34PTH, bovine 1-84PTH and human 1-84PTH. 
Table 4.3 summarises the results of these displacement studies. The 1D1 antibody 
is of low affinity. 9E3 does not recognise the intact 1-84PTH. The antibodies 3B3 
and 6E3 are equivalent in their displacement of both 1-34PTH and 1-84PTH, and 
were therefore chosen for further study.
It is apparent from Table 4.1 that attempts to produce antibodies to the C - 
terminal fragment of PTH proved unsuccessful. However two potentially 
complimentary monoclonal antibodies were available from other centres for 
evaluation in conjuction with the 3B3 and 6E3 antibodies. The monoclonal antibody 
coded E10A10, supplied by Dr. S.J. Woodhead (Cardiff), is specific for an epitope 
in the region of 44-68PTH. Monoclonal antibody ESQ-1 produced in Edinburgh by 
Dr. K. James is specific for the 74-84 region of parathyroid hormone.
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Figure 4.3 Antibody titres of sequential ascitic fluid taps.
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4.3 DEVELOPMENT OF A TWO-SITE IMMUNORADIOMETRIC
ASSAY
The selection of the best complimentary pair of antibodies required that 
each of the N-terminal antibodies be assessed in conjunction with each of the C - 
terminal antibodies, the utility of the combination being assessed with reference to 
signal to noise ratio.
Given that in plasma there is a significant excess of C-terminal fragments 
over intact 1-84PTH the optimum assay design should be to utilise the N-terminal 
antibodies coupled to a solid-phase to extract the intact 1-84PTH prior to 
incubation with a radiolabelled C-terminal antibody. Antibody combinations were 
therefore assessed using radiolabelled C-terminal antibodies and solid-phased N - 
terminal antibodies.
4.3.1 Radioiodination of Anti-PTH Monoclonal Antibodies
Radioiodination was by the lactoperoxidase method described in Chapter 2, 
section 2.2.4, using 20 pg of monoclonal antibody and 18.5 MBq of 125jocijne post 
iodination purification was by gel filtration chromatography on a 60 x 1.6  cm 
column of Sepharose 6B. The elution buffer (buffer 3) was pumped at a flow rate of 
10 ml/hour and 1 ml fractions were collected. The radioactivity of each fraction was 
counted for 10s. Iodination profiles are shown in Figure 4.4. Specific radioactivity 
of the monoclonal antibodies are calculated to be in the range 555-740 Bq/(jig.
4.3.2 Preparation of Solid-Phase Anti-PTH Monoclonal Antibodies
For screening purposes the N-terminal monoclonal antibodies were 
adsorbed onto microtitre plates. Purified ascitic fluid preparations were diluted to a 
concentration of 200 pg/ml in TAPS buffer pH 8 .6 . Each of the antibodies was 
adsorbed onto the surface of a 0.2 ml x 96 well microtitre plate by dispensing 200 
pi of antibody solution into each well and incubating at 37°C for 18 hours. The 
wells were then washed 6 times with TAPS buffer containing 0.5% BSA . 200 pi of
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Figure 4.4 Radioiodination profiles o f  two C-terminal specific  
monoclonal antibodies.
wash buffer were incubated in the wells for 1 hour at 3 7°C. Wells were then 
subjected to 3 further wash cycles.
4.3.3 Selection of a Complimentary Pair of Antibodies
Parathyroid hormone standards based on IRP 79/500 were prepared at 
concentrations of 125 pmol/1 and 250 pmol/1. Duplicate 100 pi aliquots of the 
standards were incubated for 18 hours at 4°C with each of the radiolabelled C - 
terminal antibodies (1 0 0  pi = 1 ng) in the wells of the two coated microtitre plates. 
Unbound radiolabelled antibody was then removed by washing the wells with 6  x 
0.2 ml of Taps buffer, pH 8 .6 , containing 0.5% BSA. The bound radioactivity in 
each well was counted for 60 seconds. Results are shown in Table 4.4. The signal to 
noise ratios (binding at 250 pmol/1 / binding at zero dose) suggest that ESQ-1 and 
3B3 would be the best combination. The generated signal over the lower dose range 
, the clinically relevant range, however is poor. Siddle, 1985, suggested that the 
affinity of the radiolabelled antibody has a more significant effect on the achievable 
sensitivity than does the affinity of the solid-phased antibody. The roles of these 
antibodies were therefore reversed, N-terminal antibody 3B3 was radiolabelled 
(lactoperoxidase method) and the C-terminal antibody ESQ-1 coupled to 
Sepharose CL-4B (see Chapter 2 section 2.2.3) .Sepharose CL-4B was chosen as 
the solid-phase because of its increased capacity for the uptake of antibody. This 
was thought necessary to overcome the potential interference of circulating C - 
terminal fragments. A two stage assay was performed incubating standards at zero 
concentration and 250 pmol/1 with radiolabelled N-terminal antibody (10^ cpm/100 
pi = lng/tube) for 18 hours at ambient temperature. Solid-phased C-terminal 
antibody was added (1 mg Sepharose/tube) and incubated with shaking for a further 
2 hours. Sepharose particles were then subjected to three centrifuge /wash cycles 
with 2 ml of saline containing 0.2% Tween-20. Bound radioactivity was counted 
for 60 seconds. Percentage radioactivity bound at zero dose was 0.5% while at 250
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pmol/1 was 37.5%, a 75 fold change. The capacity of the solid-phase antibody was 
further evaluated by the production of two dose response curves covering the range 
0-250 pmol/1 into one of which a 200 molar excess of C-terminal fragment (53- 
84PTH) was added. The excess C-terminal fragment had no effect on the dose 
response curve.
4.3.4 Optimisation of Assay Conditions
The basic conditions described in the previous section were used as a 
reference. Studies were performed varying buffer pH and protein content, 
radiolabelled antibody mass and specific activity, solid-phased antibody mass, 
incubation times and solid-phase wash conditions. The effects of varying 
conditions were assessed arbitrarily on the basis of improvements in signal/noise 
ratio and more specifically the precision profile and the concentration at which a 
hook effect occurred. In the interests of brevity data from the many individual 
experiments is excluded. The overall optimised conditions are as follows :-
a) Buffer -  0.1M phosphate buffer pH 7.0, containing 0.05M EDTA,
0.9% NaCl, 1% protease free BSA, 1% rat serum, 0.2% Tween-20,
0.02% NaN3 and 0.15% H2 O2 .
b) 1125 Anti-PTH -  specific activity 555-740 Bq/pg, adding 10^ cpm/tube 
in 0.1  ml assay buffer.
c) Solid-phase Anti-PTH -  1 mg/tube in 0.1 ml assay buffer.
d) Incubation period -  200 ul sample + label + solid-phase incubated with 
shaking for 22  hours at ambient temperature.
e) Wash conditions -  4 x 2 ml of 0.9% NaCl containing 0.2% Tw een-20 
and 0 .0 2 % NaN3 .
f) Standards -  standards are prepared from dilutions of synthetic 1-84PTH 
(Peninsula) in bovine serum (SAPU). The reference preparation MRC 
79/500 has a potency of 0.5 relative to the synthetic 1-84PTH.
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4.4 ASSAY VALIDATION
Assay validation is divided into two broad groups, analytical validation and 
clinical validation.
4.4.1 Analytical Validation
a) Intra assay precision.
Figure 4.5 shows a typical dose response curve and a precision profile 
constructed from duplicate analysis of 100 patient samples in a single assay. The 
precision profile data gives an estimated sensitivity of 0.5 pmol/1 (22% CV) and a 
range of 1.5-250 pmol/1 with a CV of <10%.
b) Inter assay precision
Three pools of PTH supplemented human serum are assayed in all batches. 
Table 4.5 summarises the data derived from these pools over a 3 month period. Pool 
means are 2.8, 12.6 and 18.4 pmol/1 with respective CV's of 12.6, 8.3 and 9.6%.
c) Recovery of exogenous PTH
Ten patient samples were supplemented with 10 pmol/1 of synthetic 1- 
84PTH. Each of the basal samples were assayed along with the supplemented 
samples. The basal concentrations ranged between 1.5 and 15.0 pmol/1 (mean 6.9 
pmol/1). Supplemented sample concentrations ranged between 12.0  and 25.0 pmolA 
(mean 17.6 pmol/1). The mean recovery was 107% (range 98-110).
4.4.2 Clinical Validation
The concentration of PTH 1-84 was determined in plasma from 57 
apparently healthy fasting adults. The mean value in "normal" subjects was 2.21 
pmol/1. All subjects had detectable amounts of PTH 1-84 in their plasma. The 
reference range was estimated (2 SD) as 1.0 -  4.2 pmol/1.
Twenty eight subjects with either subsequently surgically proven primary 
hyperparathyroidism or presumptive hyperparathyroidism awaiting surgery had 
plasma 1-84 PTH concentrations ranging from 5.1 pmol/1 to 100 pmol/1 (Figure
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Figure 4.5 Dose response curve and within assay precision 
profile of optimised PTH IRMA.
Table 4.5 INTER ASSAY PRECISION:PERFORMANCE 
OVER A THREE MONTH PERIOD.
Month Pool A Pool B
Mean 2.9 13.0
Feb SD 0.5 1.1
CV 16.9 8 .8
N 10 11
Mean 2.7 11.8
M ar SD 0.1 1.1
CV 5.0 9.4
N 11 11
Mean 2.9 12.9
Apr SD 0.5 0.9
CV 15.8 6 .6
N 12 12
Pool C
18.7
1.7 
9.1
i 11
17.7
1.8
10.0
11
18.9
1.9
9.8
12
4.6).
Eighteen subjects with hypercalcaemia of malignancy were also evaluated. 
Fourteen of these subjects had undetectable concentrations of 1-84 PTH. Three of 
the four remaining patients with PTH concentrations between 0.4 and 0.9 pmol/1 
had some degree of renal impairment. The fourth patient with a PTH of 2.7 pmol/1 
was also found to have an elevated urinary cAMP concentration.
Samples from six cases of hypoparathyroidism secondary to radical neck 
surgery gave undetectable 1-84 PTH concentrations.
Figure 4.6 summarises the data from these clinical groups.
4.5 CONCLUSIONS
Monoclonal antibodies to human parathyroid hormone have been produced 
the specificity of which, to some degree, was pre-determined by the choice of 
immunogen (Logue et al,1986). The most appropriate of these antibodies has been 
utilised, in conjunction with a C-terminal specific monoclonal antibody, in a two- 
site immunoradiometric assay for intact 1-84 parathyroid hormone. This is the only 
intact 1-84 parathyroid hormone assay described to-date which utilises two 
monoclonal antibodies.
Parathyroid hormone is a poor immunogen , however the response in DA 
rats was excellent. There is evidence to suggest that the choice of species or strain 
for immunisation could be particularly important when attempting to produce 
antibodies to low molecular weight peptide hormones. Immune responsiveness to 
many soluble synthetic and natural protein antigens has been found to be 
genetically controlled. These immune response genes are linked to the major 
histocompatibility complex (MHC) of the mouse, the H -2  complex. Nussbaum et al 
(1985) concluded that the immune response to human 1-34 parathyroid hormone in 
mice is genetically controlled.
In view of the high serum titres seen in the DA rats, the number of secreting
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hybrids generated from each fusion was disappointing. If it can be assumed that the 
products of fusions reflect the state of immunisation of the spleen donor then the 
results generated would suggest that either the timing of the priming dose of 
immunogen was incorrect or that the immunogen was significantly altered as a 
consequence of intravenous injection.
The use of athymic mice for the generation of ascitic fluid proved 
particularly successful posing the question as to whether the response seen was a 
feature of the animal used or the cell line injected. These animals proved easy to 
handle and they survived well with minimum barrier conditions.
The data presented in Figure 4.3 has practical implications. The increase in 
titre as a function of tap number would suggest that the later taps (3+4) have a 
greater content of specific antibody and therefore will give a greater yield of usable 
material.
The difference between the radioiodination profiles of the ESQ-1 and 
E10A10 antibodies (Figure 4.4) can be explained by the fact that E10A10 is an n - 
octanoic acid purified preparation while ESQ-1 is purified by sodium sulphate 
precipitation. This data would suggest that n-octanoic acid is more efficient than 
sodium sulphate for this purpose.
The optimised assay has a wide working range, is sensitive, precise and 
quantitatively recovers exogenously added 1-84 parathyroid hormone. The 
detection limit is such that normocalcaemic individuals have detectable 
concentrations. The estimated reference range is in agreement with previously 
published data (Newman and Ashby,1988). Initial clinical studies suggest that 
diagnostic utility is good, there being no overlap between those subjects with 
primary hyperparathyroidism and those with hypercalcaemia of malignancy (Logue 
et al, 1988). More recently this assay has been applied to a re-evaluation of 
parathyroid hormone physiology and pathophysiology (Van der Merwe et al, 1988 : 
Logue et al, 1989a : Logue et al, 1989^ : Logue et al, 1990).
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CHAPTER 5 
ATRIAL NATRIURETIC FACTOR
5.1 INTRODUCTION
Physiological experiments have repeatedly suggested the existence of 
natriuretic substances that increase the excretion of sodium from the kidney 
probably by inhibiting the reabsorption of sodium along the renal tubule ( de 
Wardner et al, 1961; Bahlmann et al, 1967).
During the 1950's several research groups performing electron microscopic 
studies of the heart noticed multiple electron-dense granules within the cytoplasm 
of atrial muscle cells (Kisch, 1956; Bompiani et al, 1959). In 1976 Marie et al 
studied the degree of granulation of these atrial cardiocytes in rats maintained on 
various water and sodium intakes. They showed a significantly greater number of 
granules in the right atrium as compared to the left and that the degree of 
granulation altered as a consequence of thirst and salt loading. Structural 
similarities between atrial granules and the granules that exist in endocrine tissues 
were first noted by de Bold (1978) leading to the speculation that atrial granules 
could contain a hormone. The same author also noted the changes in granularity as 
a function of sodium and water status (de Bold, 1979) and made the connection 
with his previous speculation. Subsequently he demonstrated that the injection into 
a rat of an extract of rat cardiac atria produced a dramatic diuresis and natriuresis 
(de Bold et al, 1981).
The search for the active component led to the independent isolation of 
several closely related peptides (Flynn et al, 1983; Atlas et al, 1984; Currie et al, 
1984; Kangawa & Matsuo, 1984), all showing the same ring of 17 amino acids but 
with varying chain lengths. This has led to a confusing terminology relating to atrial 
peptides. In retrospect the peptide heterogeneity is probably artifactual and related 
to differing degrees of damage as a result of the variety of extraction techniques 
employed. Trippodo et al (1984) proposed that the differences may indicate the 
existence of a larger precursor molecule.
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5.1.1 Nomenclature and Structure of Atrial Peptides
In 1987 a joint committee of the International Society of Hypertension, the 
American Heart Association and the World Health Organisation published 
recommendations on the nomenclature of atrial peptides (Dzau et al, 1987).This 
nomenclature will be used throughout this thesis.
It has now been established that the major active form of atrial natriuretic 
factor (ANF) released into and circulating in human plasma is a single chain 28 
amino acid peptide (Miyata et al, 1987). This peptide has a molecular weight of 
3080 daltons, and contains a disulphide bridge between residues 7 and 23 (residues 
105 and 121 of proANF). The ring structure so formed is necessary for biological 
activity (Misano et al, 1984; Hirata et al, 1985). Cloning and sequencing of 
complimentary DNA has enabled the structure of the prohormone to be deduced 
(Oikawa et al, 1984; Seidman et al, 1984). Figure 5.1 shows the structure of the 151 
amino acid peptide prepro-atrial natriuretic factor and Figure 5.2 shows the 
structural relationships of the various peptides described in the literature.
5.1.2 Biosynthesis of Atrial Natriuretic Factor
It is now generally accepted that the immediate stimulus to ANF release is 
the excitation of atrial stretch receptors by distention of the atrial wall, whether due 
to mechanical stetch (Ledsome,1985), high perfusion pressure (Dietz, 1984), or 
acute volume expansion (Lang et al, 1985a).
Prepro-ANF is encoded on chromosome 4 (Lewicki, 1986). The nucleotide 
sequence of the genomic DNA coding for prepro-ANF consists of three exons 
separated by two introns. The first exon encodes the signal peptide in addition to the 
first sixteen amino acids of pro-ANF. The second exon encodes the remainder of 
the pro-ANF molecule except the carboxy-terminal tyrosine, which is encoded by 
the third exon (Greenberg et al, 1984). Post-translational cleavage of the
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Figure 5.1 Prim ary structure o f prepro-atrial natriuretic  factor
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hydrophobic N-terminal 25 amino acid leader sequence or signal peptide generates 
a 126 amino acid prohormone, pro-ANF or ANF 1-126, which is stored in granules 
within the atrial myocyte. The C-terminal 28 amino acid peptide ANF is cleaved 
from the prohormone at the time of release into the circulation. It has a half-life in 
blood of approximately three minutes (Yandle et al, 1986^). The N-terminal 98 
amino acid fragment, ANF 1-98, is co-secreted (Michener et al, 1986); its 
biological function, if any, is unknown.
An anti-parallel dimer of ANF 99-126 has been identified in plasma and its 
biological significance is also unknown (Miyata et al, 1987). It has been suggested, 
however, that the concentration of this dimer differs in various pathological 
conditions leading to the possible conclusion that altered processing or secretion of 
abnormal forms may be involved in certain disturbances of sodium and fluid 
balance (Arendt, 1986^).
5.1.3 Biological Actions of Atrial Natriuretic Factor
Intravenous administration of synthetic ANF produces a marked diuresis and 
natriuresis. The mechanisms by which this overall effect is achieved are still 
uncertain. The kidney, the vasculature and the adrenal cortex have been identified 
as definite target organs and the combined interrelated effects of ANF on these 
organs supports the putative role of ANF as a hormone involved in sodium and 
water homeostasis. Autoradiographic and biochemical techniques have 
demonstrated the presence of specific receptors for ANF in these and other tissues 
(Napier et al, 1984; De Lean et al, 1984a; Bianchi et al, 1985; Quiron et al, 1984)
In the kidney specific ANF receptors have been localised in the glomeruli, 
vasa recta and medullary collecting duct (De Lean et al, 1985; Ballerman et al, 
1985; Murphy et al, 1985). ANF induced stimulation of cyclic GMP (cGMP) 
production, which is believed to be the second messenger of its actions (Hamet et 
al, 1984), exhibits the same distribution within the nephron (Tremblay et al, 1985;
i l l
Nonoguchi et al, 1987). The glomerular filtration rate and the filtration fraction 
show sustained elevation throughout peptide infusion and diminish abruptly when 
infusion is stopped (Needleman et al, 1985; Cole & Needleman, 1985).
The vascular effect of ANF is to relax smooth muscle. This effect is also 
mediated by cGMP (Winquist et al, 1984). It is suggested that ANF shows a 
relative selectivity to different vascular beds (Garcia et al, 1985). The decreased 
peripheral resistance caused by ANF results in a lowering of blood pressure and 
diminished cardiac output (which may be secondary to a diminished venous return 
rather than a direct cardioinhibitory effect). ANF infusion experiments on normal 
and nephrectomised rats have suggested a fluid shift from the intravascular to 
extravascular space, due to a direct effect on capillary permeability (Almeida et al, 
1986; Fluckiger et al, 1986).
Adrenal cortical cell synthesis and secretion of aldosterone is inhibited by 
ANF (Atarashi et al, 1984). This effect is also receptor mediated and seems to be 
limited to the zona glomerulosa (De Lean et al, 1984^). Inhibition is dose related. 
The experiments of Maack et al (1984) and Kurtz et al (1986) indicate that the ANF 
effect on aldosterone is both direct and via inhibition of renin release from 
juxtaglomerular cells.
The presence of ANF, and ANF receptors, in brain suggests that it may have 
neuromodulator activity (Tanaka et al, 1984; Quiron et al, 1984). ANF- 
immunoreactive neurons have been localised mainly in the cardiovascular 
regulatory areas of the central nervous system (Saper et al, 1985). In vitro studies 
using hypothalamo-neurohypophyseal preparations have shown that ANF has an 
inhibitory effect on vasopressin release (Januszewicz et al, 1986; Poole et al, 1987). 
The capillary endothelium of the blood brain barrier and the epithelium of choroid 
plexus contain ANF receptors and ANF-sensitive guanylate cyclase (Steardo et al,
1987). ANF may, therefore, have a regulatory role in the movement of water in the 
central nervous system as well as the periphery.
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5.1.4 Measurement of ANF Concentration
Bioassays measuring either the in vivo diuretic response or in vitro 
relaxation of smooth muscle were useful during the original isolation of atrial 
peptides but are not sensitive enough for the measurement of plasma 
concentrations.
Radioreceptor assays based on either rat glomerular ANF receptors 
(Ballerman et al, 1987) or ANF receptors isolated from bovine adrenal cortex 
(Burgisser et al, 1985) have been applied to the measurement of plasma ANF 
concentrations. These assays have been shown to correlate well with 
radioimmunoassays (Ballerman et al,1987 : Sagnella et al, 1987) and offer the 
theoretical advantage of measuring only biologically active forms, however, they 
have not been widely used.
Radioimmunoassay is the most commonly used method for the measurement 
of ANF concentration in plasma. Many variants have been described,which in 
general can be classified as either direct assays or those utilising a pre- 
extraction/purification /concentration step. Wide variations in reference 
concentrations are quoted ranging from 10 ng/1 (Tikkanen et al, 1985) to 300 ng/1 
(Tang et al, 1986). It is generally accepted that direct assays have a marked positive 
bias resulting from serum interference and are therefore not discussed further.
The diversity of quoted reference ranges within the extracted assay group 
can be attributed partly to physiological variations associated with sodium and 
water intake and also postural effects. Analytical variations, however, particularly 
antibody specificity, method of ANF extraction from plasma, quality of 
radiolabelled ANF and source of standard material can also be identified as 
potential contributary factors. A major point of note in this context is that 
corrections for analytical recovery are not consistently applied when reference 
ranges are calculated. Table 5.1 summarises some of the methodological variations
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in the extraction of ANF from plasma. Methodological variations associated with 
the preparation of radiolabelled ANF are described in Table 5.2. The chloramine-T 
method is most widely used but, several different procedures for post iodination 
purification are utilised.
Monoclonal antibodies to ANF have been produced (John et al, 1986; 
Naomi et al, 1987; Milne et al, 1987; Payne et al, 1987; Prowse et al, 1989; 
Mukoyama et al, 1988) and in some cases applied to the radioimmunoassay of ANF 
(Stasch et al, 1987; Naomi et al, 1988; Prowse et al, 1989). More significantly; 
monoclonal antibodies, in conjunction with polyclonal antisera, have been used to 
develop two-site immunometric assays for ANF (Lewis et al, 1989: Hashida et al,
1988). These assays do not suffer from serum interference and are sufficiently 
sensitive to allow the direct measurement of ANF concentration. Tattersall et al 
(1989) have also described a two-site immunoradiometric assay which uses two 
polyclonal antisera.
5.1.5 Plasma ANF in Pathological Conditions
In pathological conditions there appears to be a relationship between plasma 
ANF concentration and the volume status of the central circulation.
Plasma ANF rises markedly during atrial pacing (Gutkowska et al, 1985)
l
and similar elevations are seen in paroxysmal atrial I tachyarythmias (Schiffrin et al, 
1985) with prompt return to normal after restoration of normal sinus rhythm. During 
tachycardia, plasma ANF correlates with atrial pressure, not with heart rate 
(Nicklas et al, 1986), confirming the primary role of atrial pressure in the secretion 
of ANF.
In congestive heart failure the increase in plasma ANF is proportional to the 
severity of the condition (Nakaoka et al, 1985), and apparently independent of the 
nature of the underlying heart disease (Burnett et al, 1986; Lang et al, 1985^). 
Concentrations as high as ten to fifteen times normal have been found. Successful
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treatment is associated with a fall in ANF concentration (Katoh et al, 1986).
Raised circulating levels of ANF are found in volume overloaded patients 
with chronic renal failure and levels fall with fluid removal during dialysis (Wilkins 
et al, 1986).
Primary aldosteronism, which is also characterised by hypervolaemia, 
results in increased concentrations of ANF. Removal of the adenoma or diuretic 
therapy restores basal concentrations (Tunny et al, 1986).
Estimates of ANF concentrations in essential hypertension have been 
variable. Comparisons with normotensive groups have in some studies shown an 
elevation of ANF concentration with, however, some overlap between groups 
(Sagnella et al, 1986; Sugawara et al, 1985; Arendt et al, 1986^). On the contrary, 
Garcia et al (1986), found no difference in the ANF concentrations of essential 
hypertensive and normotensive subjects.
Contradictory data is also reported in patients with liver cirrhosis with 
ascites. Despite markedly expanded extracellular fluid volume, normal (Shenker et 
al, 1985), slightly elevated (Gerbes et al, 1986) and significantly elevated (Naruse 
et al, 1986) baseline concentrations have all been reported. Since increased atrial 
pressure is not a typical feature of decompensated liver cirrhosis, these data are not 
inconsistent with the view that atrial pressure is the primary stimulus of ANF 
release.
Maternal plasma blood volume increases gradually by about 40-50% during 
pregnancy (Pritchard et al, 1984). Otsuki et al (1987) have shown that plasma ANF 
concentrations also increase gradually throughout pregnancy. In addition a 
significant increase in ANF concentration was found when comparing normal 
pregnant subjects to patients with pre-eclamptic toxaemia.
It has been suggested that Bartter's syndrome might be explained as a 
syndrome of inappropriate secretion of ANF since this condition is characterised by 
volume depletion and concentrations of ANF are elevated (Tunny et al, 1986a;
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Yamada et al, 1986). Tunny et al, (1986^) also suggested, from data obtained in one 
patient, that impaired responsiveness of ANF secretion to volume loading may play 
a role in Gordon's syndrome, the mirror-image condition of Bartter's syndrome.
It is evident that the increase in plasma ANF concentration in most 
conditions is likely to be a compensatory response to the expansion of extracellular 
fluid volume and/or to elevated blood pressure rather than a cause of the 
pathophysiological event. The usefulness of ANF measurements in diagnostic or 
therapy monitoring will be equivocal until physiological and pathophysiological 
mechanisms are fully elucidated.
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5.2 MONOCLONAL ANTIBODY PRODUCTION
As this project began the structure of ANF had just been confirmed and the 
first radioimmunoassays described. From these early descriptions it was evident 
that assay sensitivity was likely to be a key problem. The variations in cited 
reference ranges and the gross differences between direct and extracted assays also 
suggested potential problems with either specificity and or matrix effects. These 
factors prompted an attempt to produce monoclonal antibodies to ANF with a view 
to developing a two-site immunoradiometric assay. The initial strategy was to 
attempt to pre-determine specificity by using synthetic fragments of ANF as 
immunogens.
5.2.1 Initial Immunisations
Synthetic ANF 99-126, the N-terminal heptapeptide (ANF 99-105) and 
the C-terminal hexapeptide (ANF 121-126) were used as immunogens. The N and 
C terminal fragments were used alone and also conjugated to KLH (keyhole limpet 
haemocyanin). These KLH conjugates were commercially prepared by Cambridge 
Research Biochemicals using N-maleimidobenzoyl-N'-hydroxysuccinimide ester 
to C-terminally couple the N-terminal heptapeptide and to N-terminally couple the 
C-terminal hexapeptide.
Each of these preparations was used to immunise three balb/c mice. Primary 
intraperitoneal immunisation in Freund's complete adjuvant was followed by two 
secondary doses in incomplete adjuvant at three week intervals. The administered 
doses of immunogens on each occasion were :- ANF 99-126 lOpg, ANF 99-105 
and ANF 121-126 50pg and KLH conjugates lOOpg. Multiple site subcutaneous 
immunisation of DA strain rats was also performed according to the same time 
schedule with a total of 50pg of ANF 99-126 being administered on each occasion. 
Test bleeds were taken from all animals three weeks after the final dose of
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immunogen.
5.2.2 Assessment of Response to Immunisation
The assessment of the response to immunisation required the production of 
radiolabelled ANF 99-126. Since this peptide has a C-terminal tyrosine residue, 
2pg were iodinated by a standard lactoperoxidase method with 18.5 MBq of 
125iodine. Post iodination purification was by gel filtration through a 28 x 1.6 cm 
column of Sephadex G25 (fine). The elution buffer was buffer 3 pumped at a flow 
rate of 16 ml/h and 0.8 ml fractions were collected. Intrinsic radioactivity was 
counted for 10 seconds. The resultant profile is shown in Figure 5.3.
Serial dilutions of test bleeds ranging from 1/50 to1/50000 were prepared in 
phosphate buffered saline (pH 7.4). 200 pi of each dilution was then incubated, at 
4°C with 200 pi of radiolabelled ANF 99-126, for 18 hours. The bound fraction 
was separated by incubation with Sepharose coupled antibody (2 mg 
Sepharose/tube), either sheep anti-mouse polyclonal antibody or sheep anti-rat 
polyclonal antibody, for 1 hour at ambient temperature. Sepharose particles were 
subjected to three centrifuge, wash, aspiration cycles with 3 x 2 ml saline.
Independent dilutions of all the test bleeds gave binding of <2.0%. Negative 
results posed the question as to whether the animals did not respond to the 
immunogens used or whether the screening assay was not detecting the response. It 
was therefore decided to check the screening assay.
5.2.3 Evaluation of the Screening Assay
Since the separation reagents used in this assay functioned well in other 
assay systems the primary target for evaluation was the 1^25 ANF 99-126 
preparation. A commercial rabbit anti-ANF 99-126 antibody, supplied by CRB 
(Cambridge Research Biochemicals), was used to assess the immunological 
integrity of the l!25 ANF 99-126 preparation.
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F igure 5.3 Gel Filtration purification of radiolabelled ANF.
Rabbit anti-ANF was serially diluted in buffer 6 and each of the dilutions 
incubated with 1^25 ANF at ambient temperature for 18 hours. Bound fraction was 
separated by a further incubation for 1 hour with Sepharose coupled DAR 
antiserum, followed by 3 centrifuge/wash cycles with 2ml of saline. The percentage 
of radioactive ANF bound is plotted against antibody dilution in Figure 5.4. The 
radiolabelled ANF had some immunoreactivity, however the maximum binding 
achieved was disappointing. This is likely to be due to either radiation damage, 
oxidation damage, deterioration of the peptide on storage or altered affinity for the 
peptide when the tyrosine residue is iodinated. The latter is unlikely since the CRB 
antibody is reported to be specific for the mid region of ANF.
To evaluate this further a 100 pi aliquot of the radiolabelled ANF (4 days 
post gel filtration) was subjected to HPLC through a Waters 0.39 x 30 cm column 
of lOp C18 pBondapak with a solvent gradient from 20% acetonitrile in 0.08% 
trifluoroacetic acid to 50% acetonitrile over 60 minutes. Flow rate was 1 ml/minute 
and 1 ml fractions were collected. Intrinsic radioactivity of each fraction was 
counted for 10 seconds. The resultant profile, Figure 5.5, shows that the single peak 
seen post gel filtration was resolved into five peaks by HPLC. An aliquot of the 
synthetic peptide was subsequently subjected to HPLC under identical conditions 
using an optical detection system, absorbance being measured at a wavelength of 
214 nm. Figure 5.6 demonstrates that the peptide prior to iodination was 
homogeneous. The rising absorbance seen from 22 minutes onwards is a function of 
the optical imbalance of the solvents used to create the elution gradient.
The heterogeneous mixture found post iodination is therefore likely to be 
caused by either radiation or oxidation damage.
5.2.4 Development of an HPLC Purification Method
The post iodination HPLC profile described above consistently produced 
multiple peaks but proved difficult to reproduce. Reported HPLC purification
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procedures using chloramine-T as the oxidising agent describe a radioiodine peak 
and two peptide peaks the latter being thought to be mono and di-iodinated forms 
of the peptide (Yandle et al, 1986).
A series of experiments were conducted in which solvent flow rate, 
concentration of acetonitrile in the starting solvent, slope of the solvent gradient, 
size of fractions collected and sample loading onto the column were modified in 
order to stabilise the resultant profile and improve the resolution of peaks.
Immunoreactivity studies using a rabbit anti-ANF (code 716/9 supplied by 
the Blood Pressure Unit, Western Infirmary, Glasgow) were conducted on the 
fractionated peaks. The final optimised conditions were :-  
Column dimensions: 30 x 0.39 cm
Column packing: Waters pBondapak C l8 10p
Solvent A: 0.08% trifluoroacetic acid
Solvent B: 70% acetonitrile in 0.08% TFA
Flow rate: 0.5 ml/minute
Starting solvent mix: 28% A in A+B
Gradient: Linear to 60% B in A+B over 96
minutes
Fraction size: 0.5 ml
These conditions consistently demonstrated resolution of the lactoperoxidase 
iodination mixture into five peaks (Figure 5.7). In immunoreactivity studies with 
polyclonal anti-ANF peak 1 showed no binding and was confirmed as unreacted 
iodine by gel filtration selecting only the protein peak only for HPLC. Peaks 2-5  
showed varying degrees of immunoreactivity, percentages of maximum binding 
being 37, 63, 35 and 57 respectively, with peaks 3 and 5 exhibiting better 
immunoreactivity.
A simultaneous optical trace (Figure 5.8) resolved six peaks C, D, E and F 
corresponding to 2, 3, 4 and 5 on the radiotrace. Peaks A and B could therefore be
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confirmed as uniodinated peptide. It had previously been shown that the ANF 
peptide prior to iodination is homogenous (Figure 5.6) therefore the oxidation 
reaction appears to have generated a derivatised form of ANF. Given the primary 
structure of ANF, this is most likely to be a methionine sulphoxide form of ANF.
This postulate was tested by a series of experiments in which simultaneous 
optical and radiotraces monitored the products of lactoperoxidase iodinations of 
ANF 99-126 and Met[O]110 ANF 99-126. The native peptides were also 
individually subjected to HPLC together with a commercial mono iodotyrosyl ANF 
99-126 supplied by Amersham International. The resultant profiles are shown in 
Figure 5.9. These experiments confirmed the identity of all peaks:-
Peak 1 unreacted iodine
Peak A unreacted Met[O]110 ANF 99-126
Peak B unreacted ANF 99-126
Peak C/2 mono iodo Met[O]110 ANF 99-126
Peak D/3 mono iodo ANF 99-126
Peak E/4 di-iodo Met[O]110 ANF 99-126
Peak F/5 di-iodo ANF 99-126
However, the demonstration of four immunoreactive peaks on the radiotrace 
and six peaks on the optical trace is at variance with previously published reports of 
HPLC purification of ANF post iodination. Since these reports all describe 
chloramine T iodinations it was decided to use the developed HPLC purification 
method to ascertain whether the differences observed were related to the method of 
iodination.
5.2.5 Comparison of Radioiodination Methods
The chloramine T method was examined because of its widespread use and 
to see if the differences observed on lactoperoxidase iodination are attributable to
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Figure 5.9 Comparison of radio and optical HPLC profiles for ANF 99-126 
and Met[O]110 ANF 99-126 before and after iodination. A 
commercial mono-iodo ANF 99-126 is shown for reference
iodination method. Radioiodination methods using Iodogen (Fraker & Speck, 1978) 
or N-bromosuccinimide (Reay, 1982) as oxidising agent have been reported to be 
less damaging to peptides and proteins. These were therefore examined to see if 
they offered any improvement in comparison with the lactoperoxidase method.
ANF 99-126 (5 pg) was reacted with 37 MBq l^ io d in e  by eacjj 0f the 
above methods (Chapter 2, section 2.2.4). The HPLC purification profiles are 
shown in Figure 5.10. With chloramine T as oxidant, 35 nmol/1 final concentration, 
only three peaks were observed on the radiotrace corresponding to unreacted iodine 
and mono and di-iodinated Met[O]110 ANF99-126. This suggests that the 
chloramine T method oxidises ANF extensively. The Iodogen and NBS methods 
gave profiles similar to lactoperoxidase with the degree of incorporation of 
radioiodine varying as a function of the molar concentration of oxidant in the 
reaction mixture (Iodogen 12nmol/l : LP 4 nmol/1 : NBS 1 nmol/1). 
Immunoreactivity studies on the peaks isolated from each iodination (Table 5.3) 
showed consistently better performence for peaks D and F.
Since the chloramine T method gave poor performance as a consequence of 
over oxidation the oxidant concentrations were reduced to 6 nmol/1 and 3 nmol/1 
(approximately equivalent to the lactoperoxidase method) and the experiments 
repeated. Radiotraces (Figure 5.11) improved marginally producing some mono and 
di-iodo ANF 99-126 but there was still a marked preferential production of mono 
iodo Met[O]110 ANF 99-126.
The alternative iodination methods did not offer any advantages in 
comparision to lactoperoxidase, the chloramine T method in particular proven to be 
inappropriate for the production of mono iodo ANF 99-126 (Perry et al, 1987).
5.2.6 Further Immunisations
Having successfully derived a reproducible method for the production of 
highly purified 1^25 mono iodo ANF 99-126 further immunisations were
1 2 2
Counts
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32300
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24
100
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Figure 5.10 Comparison of the HPLC radioiodination profiles for ANF 99-126 
by four methods. LP=Lactperoxidase : C T=C hloram ine T : 
NBS=N-Bromosuccinimide
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Figure 5.11 Comparison of the HPLC radioiodination profiles for ANF 99-126 
by chloramine T at three molar concentrations
performed. The immunogens used were the ANF 99-105 and ANF 121-126 KLH 
conjugates and bovine serum albumin conjugates of ANF 99-126, ANF 99-105, 
ANF 121-126, ANF 99-109 and ANF 111-126 prepared by the method of Staros 
et al (1986) (Chapter 2, section 2.2.5).
Three balb/c mice and three first generation crosses of balb/c and NZB mice 
were immunised intraperitoneally with 50 pg of each immunogen according to the 
time schedule previously described. Test bleeds were taken from the tail veins of all 
animals following the final dose of immunogen. Screening of test bleeds for the 
presence of specific antibody revealed that the ANF 121-126 KLH conjugate 
elicited a response in the NZB/balb/c FI hybrids, all other tests were negative. 
Figure 5.12 shows the responses obtained in NZB/balb/c FI hybrids to the C - 
terminal (M1-M3) and the N-terminal (M4-M6) KLH conjugates.
A further 5 NZB/balb/c FI hybrids were immunised with ANF 121-126 
KLH conjugate according to the same schedule and a definite response, although of 
low titre, was seen in four of the five animals (Figure 5.13).
The spleens of these animals were subsequently used in a series of 
hybridisation experiments.
5.2.7 Hybridisation Experiments
Initially eight hybridisation experiments were conducted. The selected 
animal for each experiment was given a priming intravenous dose of ANF 121-126 
four days prior to the experiment and in some cases an additional intraperitoneal 
dose of the conjugated peptide 10 days prior to fusion. This variation had no 
apparent effect on the outcome of the experiment. At splenectomy abdominal 
distension was noted in several of the sacrificed animals caused by splenomegaly, 
fluid retention in the peritoneal cavity or both. Spleen weights were variable 
ranging from 190 mg to 1900 mg. Cardiac punctures were performed to retrieve 
serum from the sacrificed animals. Each hybridisation experiment consisted of three
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Figure 5.13 Antibody dilution curves for a fu rther five NZB/Balb/c 
F I hybrid mice im m unised with ANF 121-126 KLI1 
con jugate .
separate fusions as previously described in Chapter 3.
5.2.8 Assessment of Fusion Experiments
All fusions generated growing hybrids in approximately 50% of the seeded 
wells. The rate of hybrid growth was consistent with previous experiments and 
supernatants were removed for testing 10-12 days post fusion. The screening assay 
involved the incubation of 50 pi of supernatants with 1125 mono iodo ANF 99-126 
for 18 hours followed by separation of the bound fraction with Sepharose coupled 
polyclonal sheep anti-mouse y-globulin antibody. Serial dilutions of mouse serum, 
previously shown to contain specific antibody on examination of tail vein bleeds, 
were used as positive controls in the screening assay.
In four of the eight hybridisation experiments no specific antibody 
containing wells were identified. The four remaining experiments generated 66  
wells in which binding of >10% was demonstrated. However, on visual inspection 
of these wells the majority were found to contain no growing hybrid cells. 
Presumably the antibody detected was derived from cells which had subsequently 
died. In total the contents of 31 wells were cloned by limiting dilution. Subsequent 
testing of supernatants from cloning plates, despite adequate hybrid growth, showed 
that no secretors of specific antibody had survived. This finding is not consistent 
with previous experience with GH antibodies (Chapter 3, section 3.2.4.) or PTH 
antibodies (Chapter 4, section 4.2.3.).
The most common reasons for an inability to successfully clone by limiting 
dilution are chromosomal changes or over growth by other hybrids. In the light of 
obvious splenomegaly and the knowledge that KLH is a potent immunogen a third 
possible explanation may be that the separation component of the screening assay is 
compromised by a high concentration of antibody specific for KLH. The efficiency 
of Sepharose coupled sheep anti-mouse y-globulin as a separating reagent was 
therefore examined.
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5.2.9. Examination of the Efficiency of Separation.
The efficiency of the Sepharose coupled sheep anti-mouse y-globulin 
(SAM) was tested by comparison with a polyethylene glycol/y-globulin 
precipitation separation system. The optimum concentrations of PEG and bovine 
y-globulin were determined by adding a radiolabelled mouse anti-TSH monoclonal 
antibody to a 1/400 dilution of normal mouse serum and precipitating the antibody 
with a combination of PEG and bovine y-globulin at various final concentrations 
(2-20% and 0.01-1% respectively). Final concentrations of 10% PEG and 0.1% 
bovine y-globulin were found to be optimum.
The relative efficiency of these two separation methods was assessed by 
comparison of their ability to precipitate a radiolabelled monoclonal anti-TSH in 
the presence of normal mouse serum and serum derived from a mouse immunised 
with ANF 121-126 KLH conjugate. Dilutions of the two mouse sera were prepared 
from 1/50 to 1/6400. Samples (100 pi) of each dilution were mixed with 200 pi of 
radiolabelled anti-TSH (20000 cpm). Precipitation of radiolabel was by the 
addition of either 200 pi of Sepharose coupled SAM (2mg/tube), followed by three 
centrifuge/wash cycles with 2 ml of saline, or 200 pi of 0.5% bovine y-globulin and 
500 pi of 20% polyethylene glycol 6000 followed by mixing and centrifugation at 
2 0 0 0  rpm for 20  minutes.
Figure 5.14 illustrates the impaired efficiency of solid-phase sheep anti­
mouse separation in the presence of serum from an immunised mouse. The 
polyethylene glycol/y-globulin system was not affected.
This experiment was repeated substituting 1^25 ANF 99-126 for the 
radiolabelled anti-TSH monoclonal antibody and incubating for 18 hours prior to 
separation thus creating a standard antibody dilution experiment with a non­
specific binding estimate (derived from the data on the normal mouse serum) for 
each dilution. The results, corrected for non-specific binding, clearly demonstrate
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the greater efficiency of the polyethylene glycol/y-globulin system at low serum 
titres (Figure 5.15) and that the solid-phase SAM system was compromised when 
examining test bleeds from animals immunised with KLH conjugates. This would 
also indicate the potential for problems when screening supernatants where very 
high concentrations of anti-KLH antibodies are present. A further series of 
hybridisation experiments were conducted using the polyethylene glycol separation 
system in the screening assay.
5.2.10 Assessment of Further Hybridisation Experiments
Three further hybridisation experiments were performed. The supernatants 
from 61 wells were identified as giving binding in excess of 2 0 %, this level of 
binding being chosen as an indicator of positivity since the PEG/y-globulin system 
was known to give non-specific binding levels of approximately 12%. Again, 
several of these wells on visual inspection did not contain viable cells. The contents 
of 25 wells were cloned by limiting dilution. Supernatants were tested 14 days post 
cloning and screening showed that no secretors had survived. This would suggest 
that chromosomal losses or over growth by non secreting hybrids are responsible 
for the inability to successfully clone secreting cell lines rather than inadequacies of 
the screening assay.
After 33 fusions had been performed, and consequently over 15800 wells 
screened, over a two year period, four monoclonal antibodies and a polyclonal 
antibody became available from other sources. It was therefore decided not to 
pursue the production of further antibodies but to attempt to utilise those available.
5.3 CONCLUSIONS
The production of monoclonal antibodies to ANF 99-126 has proved to be 
particularly difficult. This is primarily due to the fact that this peptide shows 
considerable sequence homology between species and is not therefore a good
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immunogen. Substitution of the methionine residue at position 110 with isoleucine 
is the only variation reported in the mouse, rat and rabbit. The ANF 121-126 KLH 
conjugate was the only immunogen to produce a response and then only in 
NZB/Balb/c FI hybrid mice. The implications of this observation will be considered 
further in Chapter 7.
The detailed experiments on radioiodination and post iodination purification 
of ANF 99-126 question the validity of a number of reported assays for the 
measurement of ANF due to their use of radiolabels produced by the chloramine T 
method. It has been demonstrated clearly that this method produces 1^25 
Met[O]110 ANF 99-126 and therefore a heterogeneous assay system. The 
specificity of antisera and the handling of standard material and samples in this 
situation is of critical importance. Immunoreactivity studies (Table 5.3) under 
standard conditions using rabbit anti-ANF (code 716/9) indicate that this antibody 
has a greater avidity for non oxidised ANF. Rosmalen et al (1987) confirmed these 
observations.
The use of simultaneous optical and radiotraces (Figures 5.7-5.9) 
demonstrates that the lactoperoxidase iodination method does not iodinate all of the 
peptide and that some of the peptide is oxidised but not iodinated. This has 
implications for the calculation of specific activity of radiolabelled peptides.
Results in Figure 5.10 show a gradation of oxidation and iodination related 
to the molar concentration of oxidant used in each of four iodination methods. 
Reaction times are considerably different, however, ranging from 10 and 15 
seconds respectively for the chloramine T and N-bromosuccinimide methods to 10 
minutes for the iodogen and lactoperoxidase methods. This suggests that the same 
end result could be achieved by any of these methods given the correct balance 
between oxidant concentration and incubation time. However this view is not 
supported by the chloramine T data in Figure 5.11 which shows that despite a 
reduction in the molar concentration of oxidant to that of the other methods,
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Met[O]110 ANF is still produced preferentially. This evidence suggests that use of 
chloramine T is inadvisable due to the poor yield of mono iodo ANF 99-126.
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CHAPTER 6
DEVELOPMENT OF AN ASSAY FOR THE MEASUREMENT OF ANF 
CONCENTRATION IN PLASMA
6.1 INTRODUCTION
Three monoclonal antibodies to ANF coded ESA4, ESA5, and ESA9 were 
supplied, in the form of both neat ascitic fluid and Protein A purified IgG, by Dr C. 
Prowse (Royal Infirmary, Edinburgh). The isotypes of these antibodies are IgG2a, 
IgG2b and IgGl respectively. Antibodies ESA4 and ESA5 appear to be directed to 
the 105-110 region of ANF99-126 and insensitive to the substitution of the 
methionine residue for isoleucine at position 110. Antibody ESA9 recognises 
human ANF105-126 but not rat ANF103-126 suggesting a binding site which 
includes the methionine residue at position 110 , and requires an intact bridge 
between residues 105-121 (Prowse et al, 1989).
A fourth monoclonal antibody was supplied by Dr A. Thakur (Middlesex 
Hospital). This antibody, coded 3H5, was supplied as dilute ascitic fluid. The 
antibody binding site has been reported to be in the 99-109 region of ANF99-126 
(Payne et al. 1987).
These four monoclonal antibodies along with the rabbit polyclonal anti- 
ANF (716/9), supplied by the Blood Pressure Unit of the Western Infirmary 
Glasgow, were examined with a view to their utilisation in either a two-site 
immunoradiometric assay or a radioimmunoassay.
6.2 ASSESSMENT OF ANTIBODY TITRES AND RELATIVE
AFFINITIES
Serial dilutions of the five antibodies ranging from 1/500 to 1/409600 were 
prepared in buffer 6 . Aliquots (100 pi) of each dilution were incubated for 18 hours 
at ambient temperature with 100 pi of l!25 ANF99-126 (10 pg/tube) and 100 pi of 
buffer 6 . The bound fraction was separated by a further incubation with 100 pi 
(lmg/tube) of either Sepharose coupled sheep anti-mouse gamma globulin or 
donkey anti-rabbit polyclonal antibody, followed by three
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centrifuge/wash/aspiration cycles with 2 ml of saline. Radioactivity in each tube 
was counted for two minutes. The percentage of 1^25 ANF99-126 bound is shown 
as a function of antibody dilution in Figure 6.1.
A parallel experiment was conducted in which the 100 pi of buffer in the 
primary incubation mixture was replaced with 100 pi of ANF 99-126 at a 
concentration of 1880 ng/1. The percentage of bound 1^25 ANF 99-126 displaced 
by this concentration of "cold" ANF 99-126 is plotted for each antibody dilution in 
Figure 6.2.
The polyclonal antibody 716/9 and the monoclonal antibody ESA4 have 
higher affinities for ANF 99-126 than the three other monoclonal antibodies. 
These' two antibodies would therefore be considered as having the greatest 
potential for producing immunoassays with maximal sensitivity.
6.3 ASSESSMENT OF ANTIBODY COMPLEMENTARITY
The assay method of choice would be a two-site immunometric assay. This 
would require two antibodies directed to independent epitopes. To ascertain 
whether amongst the five antibodies available a complementary pair existed the 
monoclonal antibodies were radiolabelled and all five antibodies coupled to 
Sepharose particles. All possible combinations were then evaluated.
6.3.1 Radiolabelling of Monoclonal Anti-ANF Antibodies
Prior to iodination the ascitic fluid containing the antibody 3H5 required 
purification. Affinity purification was chosen because of the limited amount of 
ascitic fluid available. A 5 ml column containing Protein A Sepharose CL4B was 
equilibrated with buffer 9. A 100 pi aliquot of 3H5 ascitic fluid was applied to the 
column. Buffer 9 (pH 9.0) was the pumped through the column at a flow rate of 12 
ml/h. The absorbance of the column effluent was monitored at a wavelength of
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280nm. When the absorbance generated by non bound material returned to baseline 
buffer 10 (pH 6.0) was pumped through the column at the same flow rate to release 
bound immunoglobulin. The fraction containing immunoglobulin was collected. 
The column was then regenerated by pumping first buffer 10 (pH3.0) and then 
buffer 9 (pH9.0) each for three hours. The absorbance profile obtained is shown in 
Figure 6.3. Finally the collected immunoglobulin fraction was concentrated x40 and 
the buffer switched to buffer 1 using the Amicon Centricon System with a 
molecular weight cut-off of 30000.
The Protein A purified fractions of the four monoclonal antibodies were 
iodinated by the chloramine T method (Chapter 2, section 2.2.4). Post iodination 
purification was by gel filtration through a 25 x 1.6 cm column of Sephadex G25. 
The elution buffer was buffer 6 pumped at 30 ml/hr and 1ml fractions were 
collected. Iodination profiles are shown in Figure 6.4.
6.3.2 Coupling of Monoclonal Antibodies to Sepharose CL4B
Sepharose CL4B was activated and 50 pi aliquots of the neat ascitic fluids 
were coupled to 5 ml aliquots of activated gel by the method described in (Chapter 
2, section 2.2.3). The concentration of Sepharose particles in each case was 
adjusted to 10 mg/ml. The efficiency of coupling was tested by incubating duplicate 
100 pi aliquots (lmg/tube) of each preparation with 100 pi 1^25 ANF99-126 (20 
pg/tube) for 2 hours at ambient temperature with constant agitation. Bound 1^25 
ANF99-126 was separated by three centrifuge/wash/aspiration cycles with 2 ml of 
saline. Sepharose coupled sheep anti-mouse antibody was used as a negative 
control. Results of these binding experiments (Table 6.1) indicate successful 
coupling. The lower binding achieved by solid phased 3H5 antibody reflects the use 
of dilute ascitic fluid.
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Figure 6.4 Iodination profiles of anti-ANF antibodies.
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6.3.3 Coupling of Polyclonal Anti-ANF (716/9) to Sepharose CL4B
Since the amount of this material available was limited it was decided to 
couple this antibody to solid phase indirectly. A polyclonal donkey anti-rabbit 
antibody (supplied by SAPU) was therefore coupled to Sepharose CL4B by the 
method described in Chapter 2, section 2.2.3. A 3 ml aliquot of this material (10 mg 
Sepharose/ml) was mixed with 3 ml of a 1/500 dilution of rabbit anti-ANF (716/9) 
and incubated at ambient temperature with constant mixing for 60 minutes. 
Unbound anti-ANF was then removed by subjecting the Sepharose particles to 
three centrifuge/wash/aspiration cycles with 10 ml of buffer 1. Particle 
concentration was then adjusted to 10 mg/ml. This material was tested in the same 
manner as the coupled monoclonal antibodies (described in section 6 .3 .2 ) and 
binding of 63% of added ll25 ANF 99-126 was observed.
6.3.4 Assessment of Complementarity
Each of the four radiolabelled monoclonal antibodies and the five solid 
phase coupled antibodies were used in conjunction with each other in the following 
protocol:-
100 pi radiolabelled monoclonal antibody 
100 pi ANF99-126 (320 ng/1)
Incubate for 1 hour at ambient temperature
200  pi solid phase coupled antibody
Incubate for 1 hour at ambient temperature (constant agitation)
Centrifuge/wash/aspiration x3 with 2 ml saline
Count radioactivity for 60 seconds
A second set of tubes was prepared in parallel in which the ANF99-126 in the 
primary incubation mixture was replaced with 100 pi of buffer 6 . The percentage of 
the radiolabelled monoclonal antibodies bound was calculated for each combination
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(Table 6.2), the buffer substitution providing a blank in each case. Results indicate 
that no complementary combination of these antibodies was found and therefore a 
two-site immunometric assay with these antibodies is not possible. Consequently 
the monoclonal antibody ESA4 was selected for use in a radioimmunoassay. This 
antibody was preferred to the rabbit polyclonal anti-ANF because of its greater 
titre.
There are several factors which determine the performance of a 
radioimmunoassay the most significant of which are the characteristics of the 
primary antibody. Inherent antibody characteristics are fundamental to the outcome 
of optimisation procedures particularly with regard to achievable sensitivity, 
working range and assay specificity.
6.4.1 Choice of Antibody Dilution
The results presented in Figure 6.2 indicate that the dilution of antibody 
likely to give an assay of maximum sensitivity is 1/6x1 0^ (final dilution). This 
dilution was therefore used in an initial attempt at a radioimmunoassay. The 
protocol was as follows :-
6.4 DEVELOPMENT OF A RADIOIMMUNOASSAY
200 pi ANF Standard
100 pi ESA4 Anti-ANF
50 (xl I125 ANF
(range 0-7520 ng/1)
(initial dilution 1/1.7 x 10^ ) 
(lOpg/tube : lOOOOcpm)
Incubate at ambient temperature for 18 hours
100 pi Sepharose CL4B coupled sheep anti-mouse (0.25 mg/tube) 
Incubate for 1 hour with constant agitation 
Centrifuge/Wash/Aspirate x4 with 2 ml of saline 
Count radioactivity for 120 seconds
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The dose response curve derived from this experiment (Figure 6.5) suggests that 
this assay would not be sufficiently sensitive for the direct measurement of ANF in 
plasma.
6.4.2 Effect of Delayed Addition of i !25a n F
The effect of delayed addition of 1^25 a n f  was assessed by comparison of 
variable incubation steps prior to the addition of radiolabelled ANF in the above 
protocol. Figure 6.6  presents the dose response curves obtained suggesting that 
some improvement in sensitivity is gained when 1^25ANF is added after a 24 hour 
primary incubation. This minor improvement again would not produce an assay of 
sufficient sensitivity to allow a direct assay.
6.4.3 Effect of the Mass of Added
The effect of the mass of l !2 5 ^ jF  added to each tube was evaluated by 
comparing the displacement achieved with a dose of 320 ng/1 ANF 99-126 for a 
range of final antibody dilutions (1/1.5-2.4 x 10^) when using masses of 1^25ANF 
ranging from 6 pg/tube to 48 pg/tube. Results (Figure 6.7) show no consistent trend 
leading to the conclusion that the mass of 1^25 a n f ,  within the range examined, 
will not improve sensitivity.
Since the primary factors concerned with determining sensitivity have been 
examined and this assay appears to be inadequate to consider direct measurements 
in plasma it was decided to attempt to simplify the assay protocol by coupling the 
primary antibody to magnetic particles. Any minor loss of sensitivity could 
probably be compensated for by a concentration step prior to assay which would be 
required in any event.
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6.4.4 Coupling of Anti-ANF to Magnetic Particles
Dynospheres XP6006 magnetic particles were supplied by Dynal (Norway) 
as a 10% solids in water suspension. Since the ratio of particles to antibody 
containing ascitic fluid which would yield the most efficient reagent was not known 
the coupling experiment was conducted using a fixed mass of particles with 
dilutions of ascitic fluid in 0.1M phosphate buffered saline (pH 7.4) ranging from 
x3 to x729. The coupling protocol was as follows
200 pi Dynospheres (20 mg in water)
50 pi Ascitic fluid (Various dilutions)
150 pi 0.1M Phosphate buffered saline (pH 7.4)
200 pi 0.4M Boric acid (pH 9.5)
Mix at ambient temperature for 18 hours
1.0 ml 1M Ethanolamine hydrochloride
containing 0.1% Tween 20 (pH 9.5)
Mix at ambient temperature for 3 hours
Particles were then subjected to two centrifuge/wash cycles with 2 ml of saline and
then resuspended in 4 ml of buffer 6 to give a final particle concentration of 0.5
mg/1 0 0  pi.
Duplicate aliquots (100 pi) of each preparation were incubated with 200 
pi of buffer 6 and 100 pi of I^^A N F for 18 hours with constant agitation. Particles 
were then washed with 2  x 1ml of saline using magnetic racks to hold the particles 
during decantation of supernatants. The bound radioactivity was counted for two 
minutes. Results (Table 6.3) show good binding for all preparations. The slightly 
lower binding seen with the x3 preparation may be a steric hindrance effect. Since 
these binding levels are all approaching maximum it is not possible to draw 
conclusions concerning coupling efficiency. Further dilutions of x9 to x2187, in 
assay buffer, of the preparations coupled from initial dilutions of x9, x81 and x729 
were therefore prepared and tested in the protocol described above. The dilution
135
Ta
bl
e 
6.3
 
CO
UP
LI
NG
 
OF
 
AN
TI
-A
NF
 
TO
 
M
AG
NE
TI
C 
PA
R
T
IC
L
E
S
c
oo <N q VO
oo CO CO »o
oo O n oo O n 00
curves (Figure 6 .8) constructed from these results show that coupling at higher 
concentrations of ascitic fluid causes an increased take up of specific antibody onto 
the magnetic particles. Figure 6.9 is a further representation of the same data in 
which the antibody dilution plotted is the product of the coupling dilution of ascitic 
fluid and the dilution of the final preparation. These curves are essentially 
superimposable allowing the conclusion that there are no steric hindrance effects.
A 1/16 dilution of the x729 preparation was used in the assay protocol 
described in section 6.4.1 . This corresponds to 3 pg of XP6006 particles /tube. The 
resultant dose response curve (Figure 6.10) is comparable in terms of sensitivity to 
that produced using a liquid phase primary antibody (Figure 6.5). It was decided to 
use this simpler assay system on concentrated plasma extracts.
6.4.5 Extraction and Concentration of ANF from Plasma
Various methods have been described for the extraction and concentration 
of ANF from plasma (Table 5.1 ). Having examined closely the behaviour of ANF 
on ODS column during the development of a post iodination purification procedure 
it was decided to utilise Sep-Pak C l8 cartridges to extract ANF from plasma.
Sep-Pak C18 cartridges were pre-activated with 5 ml of methanol and 
washed with 5 ml of distilled water. Plasma samples (4 ml) were acidified with 2M 
hydrochloric acid (0.25 ml/ml of plasma) prior to application to the cartridges (4 
ml). The Sep-Pak cartridges were then washed with 3 x 5 ml of 0.1% 
trifluoroacetic acid and the absorbed peptide eluted with 2  ml 60% 
acetonitrile/0.1% trifluoroacetic acid into polypropylene tubes. The extracts were 
then snap frozen in liquid nitrogen and freeze dried. Immediately prior to assay 
extracts were reconstituted in 0.5 ml of buffer 6 .
The recovery of this method was initially examined by adding 200 pi 
i!2 5 a n p  to plasma samples, processing these samples through the extraction 
procedure and reconstituting the dried extract with 200 pi of buffer 6 . Comparison
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Figure 6.10 ANF radioimmunoassay dose response curve 
for magnetic particle assay.
of counts added to counts recovered from 10 samples gave a mean recovery of 
91%. This experiment took no account of the age of the 1^25 Ajqp use(j ancj js 
therefore likely to be a slight underestimate. Recovery is satisfactory and the 
procedure introduces a 6.4 fold concentration of ANF.
6.4.6 Recovery of Exogenous ANF from Plasma
Having determined that adequate recovery is obtained from the 
extraction/concentration procedure it was necessary to combine this procedure with 
the assay of ANF concentration in the extracts and ascertain the recovery of the 
total system.
Aliquots (4 ml) of plasma from a "normal" male volunteer were 
supplemented with synthetic ANF99-126 at three concentrations. These along with 
a 4 ml aliquot of the original sample were extracted on Sep-Pak C18 cartridges and 
the extracts assayed by the previously described method. Recovery of exogenous 
ANF (Table 6.4) was found to range between 90 and 111%. This was considered 
acceptable. The measured concentration in the basal sample of 203 ng/1 however, is 
high relative to "normal" values cited in the literature. Four possibilities were 
considered for this apparently elevated basal concentration.
Firstly, the result obtained may be a true reflection of the ANF 
concentration in this individual. Further basal estimations on five more volunteers 
ranged between 85 and 150 ng/1. These results were still considered to be elevated.
The remaining three factors were a possible loss of standard potency on 
storage, differences in the oxidation state of samples and standards, or a cross 
reacting substance.
6.4.7 Confirmation of Standard Potency
The standard material used in the above recovery experiments was 
synthetic ANF99-126 supplied by Bachem. Working standards were prepared in
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buffer 6 and stored at -20°C and at the time the experiments were conducted were 
approximately six months old.
New standards were prepared, from fresh synthetic ANF99-126 supplied 
by Peninsula Laboratories, covering the range 0-8000 ng/1. Old and new standard 
preparations were assayed simultaneously and dose response curves constructed 
(Figure 6.11). These curves indicate that if there is any significant difference the 
old standards are slightly more potent than the new. This would result in higher 
concentrations in samples if the new standards were used.
6.4.8 Effect of Oxidation State of Standards and Radiolabelled ANF
a) Avidity of ESA4 anti-ANF for i125anF99-126 and I^^M et[0]A N F99-126 
Since HPLC purification of ANF post iodination isolates mono iodinated oxidised 
and non oxidised forms it is possible to relate count rate directly to mass if account 
is taken of the purity and decay characteristics of 1 ^ Iod ine an(j counting 
efficiency of the gamma counter used. The avidity of ESA4 for i125anf99-126  
and I125Met[0]ANF99-126 was determined by conducting self displacement 
experiments with each of these preparations.
Anti-ANF coupled to magnetic particles (100 pi) was incubated with 200 
pi of buffer 6 and 100 pi of serial dilutions of each radiolabelled ANF preparation. 
For each radiolabel dilution duplicate total radioactivity reference tubes were 
prepared along with non specific binding tubes in which the anti-ANF preparation 
was replaced with an XP6006 coupled monoclonal anti-TSH antibody. Following 
an 18 hour incubation, with constant mixing, particles were washed and counted as 
described in section 6.4.4. Results were used to construct Scatchard plots (Figure 
6.12) from which the avidity and the concentration of antibody were estimated. The 
concentration of antibody in both cases was 9 pmol/1 and the avidity constants for 
i125anF99-126 and I^2^Met[0]ANF99-126 were 6 .8  x 10^0 1/mol and 1.0 x 
1 0 ^1 1/mol respectively.
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Figure 6.12 Scatchard plots assessing the avidity constants 
of anti-ANF (ESA4) for I2 S I ANF 99-126 and 
12SI M et[0] ANF 99-126.
b) Comparison of Met[0]ANF99-126 and ANF99-126 Standard Preparations. 
Synthetic Met[0]ANF 99-126 supplied by Peninsula Laboratories was used to 
prepare standards over the range 0-8000 ng/1. These and ANF 99-129 standards 
were assayed simultaneously, 1*25 ANF 99-126 being used as the radiolabel. The 
dose response curves obtained (Figure 6.13) suggests that the Met[0]ANF 99-126 
standards are slightly more potent. This is consistent with the small difference in 
avidity constants derived in the previous experiment.
If the ANF 99-126 standard is totally oxidised on storage this could give a 
25% lower estimate of the basal concentrations in plasma. This magnitude of 
difference would still leave basal concentrations high relative to published data.
6.4.9 Further Examination of Plasma Extraction Procedure
Previous experiments have indicated that the recoveries of 1^25 ANF from 
the Sep-Pak columns, and exogenous ANF from plasma processed through the total 
assay procedure are acceptable. Basal concentrations of ANF however appear to be 
elevated relative to published data. Since standard potency has been confirmed and 
differences in sample/standard/radiolabel oxidation states found not to account for 
these apparently elevated concentrations the possibility of a cross reacting 
substance was considered. The presence of a cross reactant would invalidate the 
assay unless it could be removed by the initial extraction procedure. This was 
therefore examined within this context.
Eight aliquots of acidified plasma (4 ml) from a single volunteer were 
subjected to Sep-Pak extraction as described in section 6.4.5 each aliquot however 
being eluted from the column with a different concentration of acetonitrile in 0 .1% 
trifluoroacetic acid (range 15-60%). Eluents were snap frozen, freeze dried, 
reconstituted and assayed as previously described.
A simultaneous experiment was conducted in which 1^25 ANF was added
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to a 40 ml aliquot of the same plasma sample and aliquots of this (8  x 4 ml of 
acidified plasma) extracted as above. Aliquots (200 pi) of column eluents were 
counted for 120 seconds and the recovery of 1^25 ANF calculated for each 
concentration of acetonitrile used for elution from the column.
The results of these two experiments are presented together in Figure 6.14. 
The recovery of 1^25 ANF reaches a plateau of approximately 84% at acetonitrile 
concentrations in excess of 35%. Plasma ANF concentration also reaches a plateau 
at this concentration of acetonitrile, however a further rise in plasma concentration 
is seen as the acetonitrile concentration exceeds 50%. These experiments suggest a 
substance other than ANF is extracted from plasma and eluted from Sep-Pak 
columns at concentrations of acetonitrile in excess of 50%. Modification of the 
extraction procedure would eliminate this cross reactant.
6.5 CONCLUSIONS
The five antibodies examined did not provide a complementary pair 
suitable for use in a two-site immunometric assay. While the affinity of the 
monoclonal antibody ESA4 was not sufficient to allow consideration of a direct 
radioimmunoassay it has been demonstrated to be suitable for use in an indirect 
assay. There is some indication that this antibody is not absolutely specific but that 
this problem can be overcome by careful design of the extraction /concentration 
procedure prior to radioimmunoassay.
The major cause for concern is the variability of estimations on "normal" 
individuals, and the apparently high concentrations relative to published data. 
Further detailed examinations of sampling and storage conditions and the 
parameters of the extraction/ concentration procedure are required. This in 
conjunction with assessment of the effects of physiological sources of variation, 
biological rhythm, dietary status and posture will clarify the situation.
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CHAPTER 7 
GENERAL DISCUSSION
This thesis relates the strategies and tactics in applying the new technology 
of monoclonal antibody production to the provision of a routine diagnostic 
endocrinology service. The objectives outlined in Chapter one reflect the initial 
baseline within the Institute of Biochemistry where no tissue culture facilities were 
available and there was no expertise in this area. Consequently the stated objectives 
were broad.
It is axiomatic that the key component of an immunoassay system is the 
antibody (or antibodies). Though other factors such as the choice of label or method 
of separation may be important, it is the antibody which will ultimately determine 
the performance characteristics of the system. Given that a monoclonal antibody 
with the required characteristics can readily be produced it is generally true that this 
would be preferred to a polyclonal reagent. Considerable efforts have been applied 
to the production of monoclonal antibodies to peptide and protein hormones in a 
variety of centres yet in reality the introduction of monoclonal antibodies into 
diagnostic immunoassay systems has been relatively slow. The reasons for this are 
both practical and economic. While the principles of monoclonal antibody 
production are elegantly simple the practice is an enormous undertaking, 
particularly so if the end point is seen as the incorporation of a new assay into a 
diagnostic service and not merely the production of an antibody. Within this context 
each project will have its unique problems. These may be related to the structure of 
the analyte or the physiological and pathophysiological environment in which the 
analyte is encountered in routine clinical practice. The approaches adopted in 
attempting to produce and apply monoclonal antibodies to the measurement of 
growth hormone, parathyroid hormone and atrial natriuretic factor reflect that 
uniqueness.
Having a clinical biochemistry background it seemed at the outset that the 
development of a tissue culture facility and protocols for cell fusion and hybrid 
propagation would be the most significant problem. While the scale of this
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development should not be underestimated the technical aspects of the process 
proved to be relatively simple. In the three cases examined hybridomas were always 
successfully generated. In fact the number of hybrids produced caused logistical 
problems in screening large numbers for specific antibody production. This was 
particularly so in the case of growth hormone.
Growth hormone because of the phylogenetic distance between human GH 
and mouse GH was a particularly good immunogen. This and the sensitivity of the 
screening assay procedure resulted in the production of more anti-GH secreting 
hybrids than could practically could be coped with. While this could be considered 
a success it can also be construed as a failure in that this could have been 
anticipated and a more stringent initial screening procedure adopted. The ideal 
requirements for anti-GH monoclonal antibodies to be used in a two-site assay 
apart from the obvious requirement of the highest possible affinity would include a 
lack of cross reaction with similar proteins i.e. prolactin and human placental 
lactogen. Selectivity at this stage would significantly reduce subsequent workload 
and would ensure that effort and resources were not wasted on antibodies of no 
value to the project at hand. Circular arguments exist as to whether affinity or 
specificity is of most importance in this initial selection process. Obviously there is 
little point in selecting the two most avid antibodies if they both cross react with the 
same alternative molecule. However only one antibody in a two-site assay needs to 
be entirely specific since assay design considerations can often overcome potential 
cross reaction problems. This is well illustrated in the case of PTH 1-84 being 
measured in the presence of C-terminal PTH fragments. The developed growth 
hormone assay proved to be precise, accurate and robust offering a significant 
extension of working range in comparison to radioimmunoassays. The clinical 
discrimination from this assay was at least equal to the RIA it replaced. The only 
disadvantage is the cross reaction in this assay system with placental lactogen and 
to a small degree prolactin. The extent of cross reaction was evaluated by means of
142
recovery estimates of added exogenous growth hormone from sera containing 
elevated endogenous concentrations of potential cross reactant. Perry et al (1991) 
illustrate the problems associated with the assessment of cross reactivity and or 
interference utilising this growth hormone assay as a model.
The need to measure PTH1-84 in the presence of significant concentrations 
of C-terminal fragments was known at the outset. This led to the use of synthetic 
fragments as immunogens to produce the desired specificity of resultant 
monoclonal antibodies. Since the early work of Lemer (1982) and Schmitz et al 
(1983) it is now well established that small peptide sequences can be used to 
produce antibodies to the intact protein of which they form a part. This approach 
frequently produces peptide specific antibodies which fail to react with the native 
molecule (Lemer, 1984) as was the case in this study. However three of the five 
antibodies isolated did recognise the native molecule.
While the numbers initially screened in the cases of PTH and ANF were 
large since few specific antibody secreting hybrids were found secondary 
evaluations were more manageable. The number of specific anti-PTH antibodies 
detected on initial screening was a little surprising in view of the high titres found in 
the sera of donor rats. The products of fusion did not reflect the state of 
immunisation of the spleen donor. A satisfactory explanation for this was not 
immediately obvious though subsequent work with ANF did suggest a possible 
source of variability in the screening assay. Detailed evaluation of the 
radioiodination and post iodination purification of ANF revealed a sensitivity of 
some antibodies to the oxidation state of the only methionine residue in the 
molecule. There is also evidence of variable degrees of oxidation as a consequence 
of variation in iodination methods and or conditions. Parathyroid hormone 1-34 
contains methionine residues at positions 8 and 18 and is therefore likely to be 
prone to the same effects. Tashijian et al (1964) have shown these methionine 
residues to be susceptible to oxidation on storage under acid conditions and that
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polyclonal antisera to N-terminal PTH can be sensitive to the oxidation state of 
PTH. Recent studies using circular dichroism have confirmed that the oxidation of 
the methionine residue, at position 8 particularly, produces substantial changes in 
the secondary structure of PTH 1-34. These changes alter the conformation of the 
PTH 1-34 peptide, resulting in reduced affinity for receptors (Zull et al, 1990). The 
1 2 5 I-PTH utilised in the screening assays for anti-PTH was purified by gel 
filtration only and was therefore likely to be a heterogeneous product.
The evaluation of the radioiodination and post iodination purification of 
125i_ANF while being a key part of the assessment of the screening assay for anti- 
ANF antibodies allowed two further more general observations. The calculation of 
specific radioactivity of radioiodinated peptides generally assumes that all 
peptide/protein molecules exposed to the reaction incorporate 125j The 
experiments detailed in Chapter five clearly show that this is not the case. 
Reduction of the molar concentration of chloramine T in iodination reactions to 
levels similar and below those utilised in the lactoperoxidase iodination method did 
not produce similar peptide oxidation profiles. This could suggest differing 
mechanisms of reaction. Perhaps the controlled release of oxidant from hydrogen 
peroxide over an extended reaction period ensures that the concentration of oxidant 
remains very low in comparison to the short exposures with chloramine T.
Apart from the logistical problems of screening assays the use of KLH 
conjugated peptides also presented difficulties. KLH being a potent immunogen 
illicits an immune response which can saturate the capacity of a solid-phase 
separation screening assay. This effect is variably dependent upon anti-KLH titres 
and titres of specific peptide antibody and is therefore more likely to be a 
significant problem when attempting to produce antibodies to poor immunogens. 
ANF was a particularly poor immunogen. In retrospect the choice of KLH as a 
carrier protein was unwise. The majority of workers who have successfully 
produced monoclonal antibodies to ANF have used thyroglobulin as a carrier
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protein and immunised balb\c mice.
In the studies with PTH 1-34 and ANF immune responses appeared to be 
strain specific. PTH 1-34 antibodies were only demonstrated in DA rats and ANF 
antibodies in NZB\balbc FI hybrid mice. This is in keeping with current theories on 
MHC restriction. Nussbaum et al (1985) in relation to PTH 1-34 illustrated a 
genetic control of the immune response. The H -2 complex of the mouse consisting 
of genes controlling multiple functions can be divided into K, I, S and D regions. I 
region genes control the immune response and also code for la surface molecules 
on macrophages and B cells. These Ir genes appear to operate at the level of the 
macrophage by a process of determinant selection. The I region can be further 
subdivided into five subregions, A, B, J, E and C. Immunoresponse genes have 
been identified in IA and IE subregions. The studies of Nussbaum et al demonstrate 
the importance of the choice of mouse strain for immunisation in the development 
of monoclonal antibodies. The choice of nonresponder mouse strains may explain 
unsuccessful attempts to raise high affinity monoclonal antibodies in many 
laboratories. The logical practical approach to raising monoclonal antibodies would 
be to immunise as many immunologically diverse inbred mouse strains as possible 
selecting only those with high peripheral titre for fusion.
The high titre response to PTH 1-34 allowed successful specific antibody 
secreting hybridoma production and isolation and the subsequent development of 
an assay capable of quantifying concentrations of 1-84 PTH in plasma. The assay 
compares favourably in terms of detection limit and working range to published 
assays for intact PTH 1-84 (Nussbaum et al, 1987; Brown et al, 1987; Frolich et 
al,1990). The validation studies show that this assay system gives quantitative 
recovery of exogenous PTH 1-84. The tolerance of a 200 fold molar excess of C - 
terminal fragments in the optimised assay will prevent interference from samples 
from patients with established renal failure where gross elevations of C-terminal 
fragments can occur. The level of interference from PTH 1-34 is unlikely to be a
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problem in clinical samples as recent evidence indicates that circulating 
concentrations of PTH 1-34 are low (Bringhurst et al, 1988). The main clinical 
application of PTH 1-84 assay is the differential diagnosis of hypercalcaemia. The 
PTH 1-84 results from this assay allow good discrimination between normal 
subjects and patients with primary hyperparathyroidism. The PTH 1-84 
concentrations in patients with hypercalcaemia of malignancy were well separated 
from those with primary hyperparathyroidism with most patients with malignancy 
having undetectable PTH 1-84 concentrations.
The process of developing a radioimmunoassay for the measurement of 
ANF concentration, while incomplete, illustrates some of the reasons for the 
diversity of reference ranges quoted in the literature. The choice of iodination 
method, extraction procedure and standard material combined with antibody 
specificity have all been shown to be problematical.
Several alternative strategies have been employed in attempts to improve the 
success rate of the monoclonal antibody production process. These strategies have 
been aimed at different areas of the process. Spitz et al (1984) described a process 
of intrasplenic immunisation designed to give a high localised concentration of 
antigen in the target organ. This procedure supposedly offered the advantage of 
maximising the number of specific B cell blasts in the spleen and minimising the 
uptake and elimination of antigen in other parts of the body. Borrebaeck (1983) 
reported a technique of in vitro immunisation. This procedure utilises the medium 
from a mixed lymphocyte culture to provide growth factors and soluble factors 
which mimic those produced by T cell helper cells thus transforming non-immune 
spleen cells into blast cells when exposed to antigen. The procedure is described as 
offering several advantages over standard techniques in that only a few micrograms 
of antigen are needed; it is possible to follow visually the induction of blast cells; 
the immunisation takes only four to five days;and importantly, the normal cellular 
control of the immune response to self-antigens seems not to function in culture.
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This latter factor may enable the induction of responses in vitro to highly conserved 
antigens which prove difficult in vivo. As an alternative to chemical and viral 
fusogens Vienken and Zimmermann (1982) have described an electrofusion 
technique. Electrofusion is based on the temporary permeabilisation of the cell 
membrane in response to electrical breakdown. This phenomenon was discovered in 
1973 (Zimmermann et al) and was first used for the electroinjection of membrane- 
impermeable substances into freely suspended cells without deterioration of cellular 
functions or membrane integrity, Lo et al (1984) attempted to overcome the poor 
efficiency and randomness of polyethylene glycol fusion techniques by using a 
receptor mediated electrically induced cell fusion technique. B-cells express on 
their surface antigen receptor immunoglobulins of the same antigenic specificity as 
the secreted antibodies. Binding of antigen to surface immunoglobulins stimulates 
proliferation and differentiation of B-cells into plasma cell. Antigen covalently 
conjugated to avidin binds to the surface immunoglobulins on B-cells. This B - 
cell-antigen-avidin complex binds to biotin covalently attached to the surface of 
myeloma cells. An intense electric field across the bulk suspension then produces 
selective fusion of cells in contact, that is, of myeloma cells with B-cells which 
make the appropriate antibody. The net effect is that the majority of resultant 
hybridomas secrete appropriate antibodies. The advantages of this technique are 
that there is selection of high affinity antibodies because of the antigen directed 
fusion and that there is a reduction in the total numbers of hybrids produced but that 
those which do grow are more likely to be secreting antibody of interest thus 
reducing the demands on screening time.
These alternative techniques have not yet found widespread favour though it 
can be seen that several of the major problems of the basic procedure could be 
overcome by the further development of in vitro immunisation and chemically 
mediated electrofusion. The combination of these techniques could be used to 
reduced MHC restriction problems and remove the need for a primary screening
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system identifying specific antibody secreting hybrids thus reducing a major 
logistical problem. A further interesting development is the genetic manipulation of 
the variable, antigen binding, regions of immunoglobulin molecules which may 
prove to be an alternative strategy for the production of monoclonal antibodies.
The aims of this thesis have largely been fulfilled. Techniques for the 
production of monoclonal antibodies have been established and used for the 
production of antibodies to both peptide and protein hormones. Selected antibodies 
have been utilised in the the development of immunoassays and these assays 
analytically and clinically validated. Many of the problems of the overall process 
have been highlighted and their solutions illustrated. Monoclonal antibodies will 
continue to play a key role in the future development of analytical services 
providing assays with improved specificity, sensitivity and speed thus increasing 
clinical utility.
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